JPS6121602B2 - - Google Patents
Info
- Publication number
- JPS6121602B2 JPS6121602B2 JP57075588A JP7558882A JPS6121602B2 JP S6121602 B2 JPS6121602 B2 JP S6121602B2 JP 57075588 A JP57075588 A JP 57075588A JP 7558882 A JP7558882 A JP 7558882A JP S6121602 B2 JPS6121602 B2 JP S6121602B2
- Authority
- JP
- Japan
- Prior art keywords
- femoxetine
- patients
- treatment
- weeks
- anorexigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 71
- 229950003930 femoxetine Drugs 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000002830 appetite depressant Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 235000019789 appetite Nutrition 0.000 claims description 12
- 230000036528 appetite Effects 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 8
- 230000007774 longterm Effects 0.000 claims description 6
- ORJNLCKHRRUOMU-OGPPPPIKSA-N (3r,4s)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 ORJNLCKHRRUOMU-OGPPPPIKSA-N 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000006215 rectal suppository Substances 0.000 claims description 4
- 229940100618 rectal suppository Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001956 orexigenic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 72
- 230000004580 weight loss Effects 0.000 description 52
- 208000016261 weight loss Diseases 0.000 description 52
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 32
- 238000000034 method Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 230000008859 change Effects 0.000 description 11
- 206010061428 decreased appetite Diseases 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 238000004260 weight control Methods 0.000 description 10
- 235000020805 dietary restrictions Nutrition 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000011866 long-term treatment Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 6
- 230000001539 anorectic effect Effects 0.000 description 6
- 230000002891 anorexigenic effect Effects 0.000 description 6
- 235000019577 caloric intake Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 229960001582 fenfluramine Drugs 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000578 anorexic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 235000019007 dietary guidelines Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
- OJSFTALXCYKKFQ-PXNSSMCTSA-N (3s,4r)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine Chemical compound C1=CC(OC)=CC=C1OC[C@H]1[C@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-PXNSSMCTSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920001412 Chicle Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 235000011339 Manilkara zapota Nutrition 0.000 description 1
- 240000001794 Manilkara zapota Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940124332 anorexigenic agent Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000019637 foraging behavior Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- -1 sutucarose Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãããæ£è
ã«ãããé£æ¬²ããã³äœéã³
ã³ãããŒã«ãªããæžéãèæ§ãçºçãããããšã®
ãªãé·ææ²»çããããã®æ¹æ³ã§ã®ããšã¢ãã»ãã³
ïŒfemoxetineïŒããã³ãã®å¡©ã®äœ¿çšãç¹ã«å°ãªã
ãšãïŒé±éã®æéã«ãããè¥æºããæ£è ã®æ²»çã«
ãããæ¹æ³ã«é¢ããã å€å¹Žã«ããããå€ãã®è¬å€ããç¹ã«è¥æºäººéã«
ããããã®ç¡é£æ¬²èªçºæ§ããã³äœéã³ã³ãããŒã«
ãªããæžéå¹æãšã«æ¡çšããããŸãææ¡ãããŠã
ãããããè¬å€ã¯ããŸããŸã®ã¿ã€ãã®ãã®ã§ãã€
ãã亀æç¥çµè奮æ§ã¢ãã³é¡ãæ¡çšãããŠãã
ããäžè¬çã«ã¯ãã®åŒ·ãäžæ¢ç¥çµç³»ãžã®åºæ¿çäœ
çšã«ããäžå®ãèœã¡çãã®ãªãããã³äžç çãšã
ã€ã奜ãŸãããªãå¯äœçšãæããããšãç¥ãããŠ
ãããä»ã®æ§é ãæã€ãååç©ãæ¢çŽ¢ããããé£
欲ããã³äœéã®ã³ã³ãããŒã«ãªããæžéã®ããã®
ç¡é£æ¬²èªçºè¬ãšããŠæäŸãããååç©ã®äžã§ã¯ã
ãã«ã¢ãã¬ããªã³ïŒNAïŒããã³ããŒããã³
ïŒDAïŒã®ç¥çµè§£æŸïŒneuronal releaseïŒãå¢å€§ã
ããååç©ãããããã®ãããªååç©ã¯ãæçšã§
ããããšãæ€åºãããŠããããæ£è ãäžè¬ã«åºã
䜿çšãããŠããè¬ã«å¯Ÿãèæ§ãçºçãããšããæ¬
ç¹ãæã€åŸåããããçµæãšããŠãé·æã®æ²»çã¯
ããŸããããªããããã¯ç¡é£æ¬²èªçºå¹æãæçšïŒ
é±éãªãããã以äžã§æ¶ããŠããªãåŸåãããã
ãã§ãããäœéæžéã®çµäºãããããå®éèæ§ã
çºçããæç¹ãéããŠæ²»çãç¶ããŠããã«ããã
ããã以åã«å°éããäœãã¬ãã«ããäœéå¢å ç¶
æ ãžåž°ã€ãŠããŸãã®ã§ããããããã€ãŠããã®ã
ããªååç©ã®æœåšç䜿çšã¯ãå®éã¯ã»ãšãã©å¶é
ãããŠããããªããªããé£æ¬²ããã³äœéã³ã³ãã
ãŒã«ããã³æžéããã°ã©ã ã¯ãç¹ã«è¥æºããæ£è
ã«ãããŠã¯ïŒé±éæ²»çã¹ã±ãžãŠãŒã«ãè¶ããŠãã
ã«ç¶ããã®ã奜ãŸããããã§ãããå ¥æãããã
ç¡é£æ¬²èªçºè¬ã®äžã§ã¯ãããšã³ãã«ã©ãã³
ïŒfenfluramineïŒã®ã¿ãïŒé±éãè¶ããæ²»çæé
ã«ãããç¡é£æ¬²èªçºããã³äœéæžéå¹æãæã€ã
ãã§ãããããããããšã³ãã«ã©ãã³
ïŒfenfluramineïŒã¯ãã»ãããã³ïŒïŒâHTïŒæå
é²æ¢å€ãšã¯ç°ãæ§æ ã®äœçšã«ãã€ãŠç¹åŸŽã¥ããã
ããã®ãšããŠç¥ãããå®éãã®æåã劚ããããš
ã«ãã€ãŠãããããã貯èµå ŽæããïŒâHTãæŸ
åºããåºæ¿æ§ã«ãã€ãŠäœçšãããããã€ãŠãå ¬ç¥
ã®ïŒâHTæŸåºåºæ¿æ§è¬å€ã®ããšã³ãã«ã©ãã³ã®
æ§èœã«åºã¥ãïŒâHTæåé²æ¢å€ãªããæå¶å€ã«
é¢ããŠã¯ãªããã®çµè«ã«ãéãããªãã®ã§ããã
ããšã³ãã«ã©ãã³ããŸãNAããã³DAãæŸåºãã
ããã«ãïŒâHTã®å¹æã¯éžæçãšãªããªãã çš®ã ã®ã¿ã€ãããã³æ§é ã®æ£è ãèæ§ãçºçã
ããããšã®ãªãé·æäœçšæ§ã®ç¡é£æ¬²èªçºæ§å»è¬å
åŸã®ããã®åªåããªãããŠãããããããããã
ã®çæãå®è³ªçã«åé€ããŠã¯ããªããæããã«ã
æãŸãããªãå¯äœçšã®ãªããè¥æºæ£è çšã®é£æ¬²ã
ãã³äœéã®æå¹ãªã³ã³ãããŒã«ããã³æžéã®ãã
ã®æ·»å ç©çãªãŸãæ¹è¯ãããç©è³ªããã³é·ææ²»ç
æ³ãžã®èŠæ±ãããã®ã§ããã ã©ããã«ãããæ¡é£Œæ 床ã®å€è³ªåãæžå°åã«ã
ããïŒâHTæåé²æ¢å€ã®å©çšå¯èœã«ã€ããŠã¯ã
ãžãšã€ãã€ãŒããã«ã³ãã«ïŒJ.E.BlundellïŒã«ã
ããInternational Journal of ObesityãïŒ1977
幎ïŒã®ç¬¬ïŒå·»ç¬¬15ã42é ã«å ±åãããŠããããã®
åè¡ç©ã®ã³ããŒã¯ãæ¬åºé¡ãæåºããéã«çšæã
ããŠããããã«ã³ãã«ïŒBlundellïŒããã³ã¬ã€ãµ
ã ïŒLathamïŒã¯ããã®åéã§ã®ãã®æè¡ãæ¡å€§
ããŠãæ¡é£Œæ 床ã®è¬å€çåæ±ãïŒæ€ç©æåã«å¯Ÿã
ãã»ãããã³ããã³ããŒããã³ã®åœ±é¿å¯èœæ§ããš
ããè«æããšã¹ã»ã¬ã©ãã€ãïŒS.GarattiniïŒãã
ã³ã¢ãŒã«ããµããã³ïŒR.SamaninïŒåãRaven
PressãããŠãŒãšãŒã¯çºè¡ã®ãCentral
Mechanisms of Anorectic Drugsããšããæ¬ã®
第83ã109é ã§çºè¡šããŠãããããã®ã³ããŒãçš
æãããŠããã第89ã90é ã«ã¯ãïŒæéã®æ¡é£Œã
ã¹ãäžã«æž¬å®ãããé£äºæ 床ãžã®ç¡é£æ¬²èªçºè¬ã®
äœçšã蚌æããå³ã瀺ãããçç£ç©ããšã¢ãã»ã
ã³ããã®å¡©é žå¡©ãšããŠç©è³ªFG4963ãšããŠè¡šãã
ããŠããããããã®å ±åè ãã¯ãããšã¢ãã»ãã³
ãæ£è ã®èæ§çºçãé¢åãªå¯äœçšããªããïŒé±é
以äžãã®éã®é·æã«ããã䟡å€ããç¡é£æ¬²èªçºè¬
å€ãšãªãããšã瀺åããŠã¯ããªããããã€ããšã¢
ãã»ãã³ã圌çã®å ±åããæžé¡äžã«é瀺ãããïŒ
æéã®é£äºæéãè¶ããŠç¡é£æ¬²èªçºäœçšãæãã
ããšã瀺åããŠã¯ããªãã®ã§ããã ãã¡ãããç¡é£æ¬²èªçºæ§è¬å€ã®åäžæäžã§é£æ¬²
ãšäœéã®æžå°ããããããšã¯ãã§ã«ç¥ãããŠãã
ããé£äºæåãšäœéãšã¯ããšã®ã¬ãã«ã«ããããŸ
æ»ã€ãŠããªããïŒã±æãªãããã以äžã®é·æç¶ã
ãããªéå°ã®é£äºæåãéé£äœèèªã®å¢å€§ãšãã€
ãçµå±ã®çµæã§ã®éé£ãšäœéå¢å ãšãªã€ãŠããŸã
ããšãããç¥ãããŠãããäŸãã°ããã®ããšã¯ã¢
ã³ããšã¿ãã³ã§ã確ç«ãããããšã§ããåç©ãã
ã³äººéã«ãããé£æ¬²æ¬ ä¹ããã³äœéæžå°ãçãã
ããååçè¬å€ãããŒãã«ïŒHoebelïŒããããª
ã³ã¹ãã³å€§åŠãã©ã€ããµã€ãšã³ã¹28å·»ã第77ã82
é ïŒ1981幎ïŒPergamon Pressã§æããã§ããã ïŒé±éãªããããããçæã®æ²»çã«ãããŠæ£è
ã«çºçããèæ§ããããããããªããããã€ãŠã
ã®ç¹ã§ãã®ãããªæ²»çã§ã¯äŸ¡å€ãæããªãç¡é£æ¬²
èªçºæ§è¬å€ã®äžã«ã¯ããžãšãã«ããããªã³ãã¯ã
ã«ããšã³ãã«ãã³ãããšã³ãã«ãã³ããããµã³ã
ãšã¿ãã³ããã³ããšã³ã¡ãã©ãžã³çãç¥ãããã
ããã¯ãDrugsãïŒ1975ïŒ10ïŒïŒïŒç¬¬241ã328é
ã®ç·èª¬è«æããã³åæžç¬¬271é å³ïŒã§ã°ã©ãçã«
瀺ãããããšãã§ããã ããšã¢ãã»ãã³ãåé çã®äºé²æ²»ççšãšããŠïŒ
é±éã«ãããïŒæ¥400mgæäžãããŠã瀺ãããå¯
äœçšã¯é£æ¬²ãšäœéã®æžå°ã§ãã€ããããããèæ§
ãç¡é£æ¬²èªçºã®èŠ³ç¹ã«ãããŠã¯è¡šãããŠããªã
ãããŸãè¡šãããŠãããªãã€ããšãã瀺åã¯ãªã
ã€ããããã®ãããªèæ§ãïŒé±éãªãããã以äž
ã«ãããæ²»çã¹ã±ãžãŠãŒã«ã«ãããŠè¡šãããªãã€
ããšããææããªããæã ãããšã¢ãã»ãã³ã§åŸ
ãçµæã®ããã€ãã¯ãAlimentazione
Metabolismo NutrizioneãïŒ1980ïŒãïŒã383ã«å ¬
ã«ãããŠããããã¯1980幎10æïŒâ11æ¥ããŒãã§
ã®è¥æºã«é¢ãã第ïŒåœéäŒè°ã§çºè¡šãããè«æã®
ã¢ãã¹ãã©ã¯ãã§ãããæ©ããŠã1980幎ã®ïŒæã«
åè¡ããããã®ã§ããã®äŒè°ã§ããã«æ€èšããã
ãŠãããããã®åŸçºå±ããçºè¡šããªãããŠããª
ãããã®çºè¡šã¯æ¬çºæåºé¡ããªãããæ¥ã®ïŒå¹Žä»¥
å ã§ããã å¯èœæ§ãæã€ãã¢ã¬ããã€ãã¯
ïŒthymolepticïŒãšããŠã®ããšã¢ãã»ãã³ã«é¢ãã
ä»ã®çºè¡šã¯ããEuropean Journal of
Pharmacologyã32ïŒ1975ïŒç¬¬108ã115é ããã³
ãPsychopharm acologiaãïŒBerl.ïŒ42ã21â26
ïŒ1975ïŒã«ç€ºãããŠãããããããã¯ç¡é£æ¬²èªçº
掻æ§ã«ã€ããŠèšåããŠããªãããŸããããšã¢ãã»
ãã³ãé瀺ããåºæ¬çãªç±³åœç¹èš±ç¬¬3912743å·
ïŒ1975幎10æ14æ¥çºè¡ïŒã§ããããããã¯ããšã¢
ãã»ãã³ã瀺ããŠãããææå¶å€ããã³æããŒã
ã³ãœã³æ»ç è¬å€ãšããŠã®ååç©ãšããŠã§ããã 掻æ§æå æ¬çºæã®çµæç©ã®æŽ»æ§ãªæåããã³æ¹æ³ã¯ãã
ãšã¢ãã»ãã³ã§ãããããã¯ïŒïŒïŒãã©ã³ã¹âïŒ
âãïŒïŒâã¡ããã·ããšããã·ïŒâã¡ãã«ãâïŒâã¡
ãã«âïŒâããšãã«ãããªãžã³ã§ããã以äžã®æ§
é åŒã®ãã®ã§ããããŸãã¯ãã®æ圹çã«éèŠãã
ãå¡©ãäŸãã°é žä»å å¡©ã§ããã 奜ãŸããããšã¢ãã»ãã³å¡©é žå¡©ããã³ããšã¢ã
ã»ãã³ãã³ãã«é žå¡©ã®ç©çå®æ°ã¯ä»¥äžã®åŠãã§ã
ãã èç¹ïŒâïŒ ãαãïŒïŒ  å¡©é žå¡© 187 ã191 74ã75.6ã ïŒæ°Žäžæ¿åºŠ0.05ïŒ ãã³ãã«é žå¡© 127.5ã130 88ã89.8ã ïŒ96ïŒ ãšã¿ããŒã« äžæ¿åºŠ0.05ïŒ çµå±ãæ¬çºæã¯ãè¥æºããããæ£è ã®é£æ¬²ãšäœ
éãã³ã³ãããŒã«ããã³æžéããã«è³ããæ¹æ³ã«
é¢ãããã®æ£è ã«å¯Ÿãå°ãªããšãïŒé±éã«ããã
ããšã¢ãã»ãã³ããã³ãã®è¬å€çã«å容ãããå¡©
ãããªã矀ããéžã°ããé£æ¬²æžéæ§ååç©ãæå¹
ãªé£æ¬²æžééã§çµå£çãªããçŽè žçã«æäžããã
ããšãããªããã®ã§ããããã®æ¹æ³ã§ã¯é£æ¬²æžé
æ§ååç©ã¯ãè¬å€çã«å容ããããã€ãªã€ãŒãšãš
ãã«æäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ãçµå£çã«ã¯çŽ100ã1000mgã®æ¥éã§æäžãã
ããããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©ã¯çŽ
400ã600mgã®æ¥éã§çµå£çã«æçšããããããã
ãŸããã®æ¹æ³ã§ã¯ãé£æ¬²æžéæ§ååç©ã¯çŽ100ã
300mgãå«æããçµå£çãªåäœæäžéã§äœ¿çšãã
ãããã®æ¹æ³ã§ã¯ãé£æ¬²æžéæ§ååç©ã¯ããã®çŽ
100mgãå«ãçµå£çãªåäœæäžéã§äœ¿çšãããã
ãã®æ¹æ³ã§ã¯é£æ¬²æžéååç©ã¯çŽè žçã«çŽ50ã
600mgã®æ¥éã§æäžããããããããã®æ¹æ³ã§ã¯
é£æ¬²æžéæ§ååç©ã¯ãã®çŽ50ã600mgãå«æãã
çŽè žãžã®åº§è¬ã®åœ¢ã§æäžãããããã®æ¹æ³ã§ã¯é£
欲æžéæ§ååç©ã¯ã掻æ§æåãšããŠçŽ300mgãå«
ãçŽè žãžã®åº§è¬ã®åœ¢ã§æäžãããããŸããã®æ¹æ³
ã§ã¯é£æ¬²æžéæ§ååç©ã¯ãïŒé±é以äžã®æéã«ã
ããæäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ã12é±é以äžã®æéã«ãããæäžãããããã®
æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©ã¯ïŒé±é以äžã®æéã«
ãããæ¯æ¥æäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§
ååç©ã¯ãå°ãªããšã12é±éã®æéã«ãããæ¯æ¥
æäžããããç¹ã«ãã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ããšã¢ãã»ãã³ã®è¬å€çã«å容ãããå¡©ä»å ç©
ã§ããããã®çŽ100ã300mgãå«æããã¿ãã¬ãã
ã®åœ¢ã§æ¥éçŽ100ã1000mgãçµå£çã«æäžãã
ãããããŠç¹ã«ãã®æ¹æ³ã§ã¯ãã®ååç©ã¯ããšã¢
ãã»ãã³å¡©é žå¡©ã§ããã奜ãŸããæ¹æ³ã§ã¯ãã®å
åç©ããïŒé±éãªãããã以äžã®é·æã«ãããã
ã®æ²»çã«åŠããããæ£è ãé£æ¬²æ¬ ä¹æ§èæ§ãçºç
ãããããšãªãæäžãããããšããããšã§ããã ãã奜ãŸããæ æ§ãšããŠæ¬çºæã®å¥ã®èŠçŽã¯ã
æ£è ã«å¯Ÿãé£æ¬²æ¬ ä¹æ§èæ§ã®çºçããããããšãª
ããé·æçããŒã¹ã§è¥æºããããæ£è ã«ãããé£
欲ããã³äœéã³ã³ãããŒã«ããã³æžéã«å©ããæ¹
æ³ãšãªããã®ã§ãããããšã¢ãã»ãã³ããã³è¬å€
çã«å容ããããã®å¡©ãããªã矀ããéžã°ããé£
欲æžéæ§ååç©ãé·æã«ãããæå¹ãªé£æ¬²æžéã®
éã ãäžèšæ£è ã«çµå£çã«æäžããæäœããšãã
ã®ã§ããã®æ¥éã¯çŽ100ã1000mgã§ãããåäœæ
çšã®åœ¢ã§ã¯çŽ100ã300mgãå«ãããã®ã§ããã ããšã¢ãã»ãã³ããã³ãã®å¡©é¡ã®èª¿è£œ ããšã¢ãã»ãã³ããã³ãã®å¡©é¡ã¯å ¬ç¥ã®ååç©
ã§ããã1975幎10æ14æ¥çºè¡ã®ç±³åœç¹èš±ç¬¬
3912743å·ã«ä»£è¡šçã«èª¬æãããŠããããšããå ¬
ç¥ã®æ¹æ³ã§èª¿è£œãããããã®ç¹èš±ã®é瀺ã¯åèã«
瀺ãããããšã¢ãã»ãã³ã¯ä»£è¡šçã«ãã®å¡©é žå¡©ã®
圢ã§ã³ãŒãçªå·GF32ã®ããšã«ç¬¬ïŒæ¬ã®è¡šã®åºã®
第ïŒã®ååç©ãšããŠç€ºãããŠããã é žä»å å¡©ã®åœ¢ã§æ¬çºæã®æ¹æ³ãæå¹ãªååãšã
ãŠæ¡çšããã«ã¯ãé žã¯å°ãªããšãéåžžã®æ²»ççæ
çšã§æ¯æ§ã®ãªãè¬å€çã«å容ãããã¢ããªã³ãå«
ããããªãã®ãšããŠéžã°ããããã®ã°ã«ãŒãã«å«
ãããããããªä»£è¡šçãªå¡©ã¯å¡©é žå¡©ãèåæ°ŽçŽ é ž
å¡©ãç¡«é žå¡©ãé ¢é žå¡©ããªã³é žå¡©ãç¡é žå¡©ãããé ž
å¡©ïŒquinateïŒãé ç³é žå¡©ããã³ãã¬ã€ã³é žå¡©ã§ã
ããä»ã®é žä»å å¡©ãé©çšãåŸãããææã§ããã°
æ¡çšããããäŸãã°ããããŒã«é žãå®æ¯éŠé žãã¢
ã¹ã³ã«ãã³é žããã¢ã€ã³é žïŒpamoic acidïŒãã³
ãã¯é žããµãªãã«é žããã¹ã¡ãã¬ã³ãµãªãã«é žã
ããããªã³é žãã°ã«ã³ã³é žããªã³ãŽé žãããã³
é žããã³ãã«é žãæ¡ç®é žãã·ãã©ã³ã³é žãã¹ãã¢
ãªã³é žããã«ããã³é žãã€ã¿ã³ã³é žãã°ãªã³ãŒã«
é žããã³ãŒã¹ã«ãã³é žãããã³ã¹ã«ãã¢ãã³é žç
ãé žä»å 塩圢æçšé žãšããŠæ¡çšããåŸããææ©ã
ãã³ç¡æ©é žãé©æãããã®ã§ããã ã«ããªã³äº€ææš¹èã§ã®å¡©ãçšãããããããã
ã¯çµå£çãªæç¶æŸåºç調補ãå¯èœã«ããããªããª
ãéé¢ã®å¡©åºãŸãã¯çç©åŠçãªåžåå€éšæããã
ãã®æš¹èå¡©ãããã€ãããšé·æéã«ããã€ãŠè§£é¢
ãããããã§ããããããã€ãŠããããæš¹èå¡©ã
åæ§ã«æ¬çºæã«ãããæå¹ãªååãšããŠæ¡çšãã
åŸãç¯å²å ã«ããã®ã§ããããã®ã»ãå¥ã®è¬å€ç
ã«å容ãããå¡©ããææãªãã°æ¡çšããããæ°å€
ãã®ãã®ãããªå¡©ã容æã«èããããåœæ¥è ã«ã
ã€ãŠã¯ãæãããªããšã§ããã äžè¬ã«æ¬çºæã®æŽ»æ§äœã¯ãéåžžã®æ¹æ³ã§éé¢ã®
å¡©åºãªãããã®é žä»å å¡©ã®åœ¢ã§èª¿è£œåé¢ãåŸãã
ã®ã§ãããå žåçãªå¥œãŸããé žä»å å¡©ã®äŸç€ºã¯ã
ã§ã«ç€ºãããšããã§ãããæ¬çºæã®æŽ»æ§äœãåºåœ¢
ãªããçµæ¶äœã®é žä»å å¡©ã®åœ¢ã§åé¢ãçšããã®ã
奜ãŸããããäœçãã®çç±ã§æŽ»æ§äœãéé¢ã®å¡©åº
ã®æ¹ã§çšããå¿ èŠããããšãã¯ãéåžžã®æ¹æ³ã«åŸ
ããåŸãããšãã§ããã§ããããäŸãã°èª¿è£œã®ã
ãã®åå¿ã溶åªäžã§è¡ãªããã€ãã§æº¶åªãèžçºã
ãããŠã»ãšãã©ç¡è²æ²¹ç¶ãšããŠåå¿çæç©ããã
ãšããåé¢ãããå¡©é žå¡©ãšãå¥ã®å¡©ãæ°Žäžã«æº¶è§£
ããã¢ã³ã¢ãã¢ãæ°Žé žåã¢ã³ã¢ããŠã ãçé žãã
ãªãŠã ãªããä»ã®é©åœãªå¡©åºæ§ç©è³ªã®ããšãå¡©åº
ã§äžåãã解é¢ãããå¡©åºãé©åœãªãšãŒãã«ãã
ã³ãŒã³ãªã©ã®æº¶åªã§æœåºããæœåºæ¶²ã也ç¥ããã€
ãã§ç空äžã§ä¹Ÿç¥ãããããåå¥èžçããããšã«
ãã€ãŠã§ãããä»å å¡©ã¯ãŸãéåžžã®æ¹æ³ã«ããé
é¢å¡©åºãã調補ãããé©åœãªæº¶åªäžã«éé¢å¡©åºã
ã²ãããã溶解ãããç¹å®ã®ææã®é žã§é žæ§å
ããå€ãã®å Žåãé žä»å å¡©ã®æ²æŸ±ã®åœ¢ãšãªããä»
ã®å Žåãææã®å¡©ã¯æº¶æ¶²ãå·åŽããããéå°ã®æº¶
åªãèžçºãããããé žä»å å¡©ã®åé¢ã®ããã®åæ§
ãªå ¬ç¥ã®æ¹æ³ã§åé¢ãããããããããå Žåã«
ã¯ããŸãé žä»å å¡©ã¯åå¿çæç©ã®äžåããã溶åª
溶液ã«ç¹å®ã®é žãæ·»å ããããšã«ãããåå¿ç©ã
ã調ç¯åé¢ããããã æäžåœ¢æ æ¬çºæã«ãã䜿çšã®ããã®åäœæäžåœ¢æ ã¯ã©ã®
ãããªé©åœãªãã®ã§ãããããåŸæ¥ã®ã¿ã€ãã®ã
ã®ã§ããããçµå£çæäžã®ããã«ã¯ãåäœæäžåœ¢
æ ã¯ãäžè¬ã«åœè©²æŽ»æ§ãªé£æ¬²æžéæ§ååç©ãçŽ
100ã300mgã奜ãŸããã¯çŽ100mgãå«æããŠãª
ããçŽè žæœçšãšããŠã®çŽè žçšåº§è¬ã®åœ¢ã§ã¯ãåäœ
æäžã¯éåžžåœè©²æŽ»æ§ãªé£æ¬²æžéæ§ååç©ãçŽ50ã
ã600mgã奜ãŸããã¯çŽ300mgãå«æããããã§ã«
è¿°ã¹ãããã«ãåœè©²é£æ¬²æžéååç©ã¯å¥œãŸããã¯
è¬å€ã«å容ããããã€ãªã€ãŒãšãšãã«ãªããçµå
ãããŠæœçšãããã åœè©²æè¡ã®éåžžã®å®æœã«ããã°ã掻æ§ãªé£æ¬²æž
éæ§ååç©ã¯äžè¬ã«æ¯æ§ã®ãªãåºäœãªãã液äœã§
ããè¬å€çãªåžéå€ãªãããã€ãªã€ãŒãšå ±çšãã
ãããããæ··åãã€ãªã€ãŒãããçš®ã®é©çšã«ãšã€
ãŠã¯å¥œãŸãããã®ã§ããããã®çµæã¯ãã¿ãã¬ã
ããç²æ«ãã«ãã»ã«ã液ç¶æº¶æ¶²ããšãã«ãžãšã³ãª
ãããµã¹ãã³ãžãšã³ãããã«çµå£çæäžã«ç¹ã«æ
å©ãªå¥ã®æçšåœ¢æ ããšãããšãã§ããã液äœãªã
ãå液äœã®åžéå€ãçµå£ç䜿çšã«ã¯æ¡çšãããã
ãã®ãããªåªäœã¯ã次ã®ããšã溶åªãšãªãåŸãã
å«ã¿ããã液äœåžéå€ã®åºæ¬çãªå¶éãšãªãããš
ã¯é©åæ§ãšå¿«é©æ§ãšã§ãããçµæã¯ããšã¢ãã»ã
ã³ãªãããã®é žä»å å¡©ãç±³ãã³ãã³ãã³ãŒã³ã¹ã¿
ãŒãããããã¹ã¿ãŒããã©ã¯ããŒã¹ããµãã«ããŒ
ã¹ããŒã©ãã³ãã¿ã«ã¯ãã¹ãã¢ãªã³é žãã¹ãã¢ãª
ã³é žãã°ãã·ãŠã ãã«ã«ããã·ã¡ãã«ã»ã«ããŒ
ã¹ãã¬ã ãäŸãã°ã¬ã ã¢ã«ã·ã¢ããã©ã¬ã³ãã¬
ã ããã¯ã«ããããŠãçã®ãããªåºåœ¢åžéå€ãã
ã³ïŒãŸãã¯ã¿ãã¬ããå©å€ãšæ··åãã圢ããšãã
è¬å€çæäœã§çšããããã¿ãã¬ããåç©è³ªã¯ãã
ããã掻æ§æåãšã®äžé©åæ§ããªããã°çšãåŸ
ãã掻æ§æåã¯ã¿ãã¬ããåããããããã®ã»ã
ä»ã®å ±æŽ»æ§ç©è³ªããªãããããªãã§ãã³ã³ããŠã³
ãåããåŸããå¥æ³ãšããŠã掻æ§æåã¯æŽ»æ§ãªã¢
ãžãŠãã³ããšå ±ã«ãªãããããªãã§ãŒã©ãã³ã«ã
ã»ã«ã®ãããªåžåå¯èœãªç©è³ªã®ã«ãã»ã«ãšãªã€ãŠ
çšãããããã®åœ¢ã§æœçšããããã掻æ§æåãé«
æ¿åºŠã«ããŠãã¿ãã¬ããåããç²è¬ã®äœ¿çšã«ãã
æ¡çšãåŸããä»ã®æ æ§ã§ããç²æ«ã®æŽ»æ§æåã¯ã¢
ãžãŠãã³ããšå ±ã«ç²æ«ã®å°å ãšãªã€ãŠçšããã
ãããã®ã»ãã«ã掻æ§æåã¯ã以äžã®ãããªæ æ§
ãšãªã€ãŠãçµæç©ãšãªããçµæç©ã¯çš®ã ã®é£ç©ãš
æ··åããåŸããé·æã®æŽ»æ§ç¶æã«ã©ãããŒãåãª
ããè žçšã«è¢«èŠãããã¿ãã¬ããã®åœ¢ã§èª¿è£œãã
ããå¶é žæãªããé®çå€ãäŸãã°æ°Žé žåã¢ã«ãã
ãŠã ã²ã«ãçé žã«ã«ã·ãŠã ãé žåãã°ãã·ãŠã ãª
ããããªã±ã€é žãã°ãã·ãŠã ãã¢ã»ãã«ãµãªãã«
é žãããšãã»ãã³ãããããã·ããšã³çãšæ··åã
ãããããšããã«ãã¿ã«ãŸãã¯ä»ã®ãã«ããã«é ž
ç³»é®çå€ãŸãã¯éº»é å€ãäŸãã°ã³ãã€ã³ãšããšæ··
åããããèè žéšäœäžã§å±æç麻é å¹æå€ãäŸã
ã°ããã«ã€ã³å¡©é žå¡©ãããã«ã€ã³çãšæ··åãã
ããå©å°¿å€ååç©ãäŸãã°ã¯ãããã¢ãžãããã
ãã¯ãããã¢ãžãçãšæ··åãããããŸãã¯ä»ã®ã¢
ãžãŠãã³ããšãå¢éå€ãäŸãã°ã¡ãã«ã»ã«ããŒã¹
ãšãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãªããäžè¿°ã®ç©
質ãšã®å ±çšçã§çšãåŸãã§ãããã掻æ§æåãäž
ã€ãªãããã以äžã®ä»ã®è¬å€çã«æŽ»æ§ãªç©è³ªãšæ··
ãããããšãã¯ããã¡ãããã®ç©è³ªãé©åæ§ãæ
ããã°ãªããæ¬çºæã®æŽ»æ§æåã®è¬å¹ãæžå°ãã
ããããŠã¯ãªããªããäžè¿°ãã圢ã®ã»ããæ¬çºæ
ã®çµæç©ã¯ãŸããã€ã³ãã€ããœããããªã³ã¯ãã¬
ã ãç³è¬ãã·ãããããšãªãã·ã«çã®åœ¢ããšãåŸ
ããã©ãããŒãçšã®ã¿ãã¬ããã³ãŒãã€ã³ã°ãšã
è žçšã³ãŒãã€ã³ã°ã®ããã®æç®ãšããŠç±³åœç¹èš±ç¬¬
1907203å·ãå第2196768å·ããã³å第2433244å·
ããããä»ã®é€ççšæŸåºã¿ã€ãã®èª¿åãšããŠãæ¡
çšãåŸããã®ã¯ç±³åœç¹èš±ç¬¬2875130å·ã§ããã
çš®ã ã®è¬å€ç調åãæäœãšããŠæ¡çšããããã®ã«
ãPharmacy for various phar maceutical
formulations and procedureããããã³ç±³åœç¹èš±
第2753288å·ããã³å第2881113å·ã®æ现æžããã³
ä»å çãªè¬å€ç圢ããã€ãªã€ãŒã調åãçµæã®ã¿
ã€ãçšãšããŠæ¬çºæã®æŽ»æ§æåã¯ãåé¡ã®ç¹èš±ã®
掻æ§æåã«çœ®æããããã®ã§ããã座è¬ãšãçŽè ž
æœçšã®ããã®çµæç©ãé©åœãªåŸæ¥ã®ã¿ã€ãã®ãã®
ã§ãããäŸãã°æŽ»æ§æåãè»èãã¯ãã¯ã¹ãããª
ãšãã¬ã³ã°ãªã³ãŒã«ããŒã¹ã奜ãŸããã¯äœæž©ä»è¿
ã§è§£ãåŸããã®ãªããå»åŠãè¬åŠåéã®åœæ¥è é
ã«ãããŠçšãåŸããã®ã«åæ£ãããããã®ã§ã
ãã æ¬çºæã®çµæã«ããã掻æ§æåã®å²åã¯å€ãã
åŸããã®ã§ãããå¿ èŠãªããšã¯æŽ»æ§æåãæå¹é
ååšããããšã§ãããããªãã¡å¥œãŸããæäžéã
ãã®æäžåœ¢æ ãšãšãã«åŸãããããšã§ãããæã
ãã«ããã€ãã®åäœæäžéã®åœ¢ã¯ãã»ãŒåæã«æœ
çšããããããŒã»ã³ããŒãžã§ç€ºãã°ãæ¬çºæã«ã
ã€ãŠæ¡çšããã奜ãŸããè¬å€ççµæã§ã®æŽ»æ§æå
ã¯ãéåžžçŽ0.1ãçŽ80ééïŒ ã奜ãŸããã¯çŽ0.5ã
çŽ60ééïŒ ã§ãããå¶é žå€ãšãä»ã®å ±æŽ»æ§ç©è³ªãš
æ··ãããããªæ¶²ç¶ãšãå¢éçã¿ãã¬ããã®å Žåã®
ããããŠäœãå Žåãšããåã«æŽ»æ§ãªé£æ¬²æžéçšãš
ãä»ã®åºåœ¢æçšåœ¢ã®ããšãã¿ãã¬ããã§ã®ããã
ãŠé«ãå Žåãšãçµæç©ã®åœ¢ã«ããå€ãããã®ã§ã
ããå€ãã®åºåœ¢æäžåœ¢æ ã¯ããŒã»ã³ããŒãžãçµæ
ç©ã®ééåœãçŽ10ã60ïŒ ã§ãããåäœæçšåœ¢æ ã®
調補ã®éãåœæ¥è ã§ããã°æ°å€ãã®åäœæäžåœ¢æ
ãèãåŸããããã®æ¬èª¬æãèªãã§ãåœæ¥è ã§ã
ãã°æçœã«åœè©²æè¡ã¯ç€ºããããã§ãããã æäžæ¥é ãã§ã«è¿°ã¹ãããã«ãæ¬çºææ¹æ³ã«ããã掻æ§
ãªé£æ¬²æžéæ§ååç©ã¯éåžžçµå£çã«ã¯æäžæ¥éçŽ
100ã1000mgã奜ãŸããã¯çŽ400ã600mgã®æœçšã§
ããããŸãçŽè žæœçšã§ã¯éåžžæäžæ¥éçŽ50ã600
mgã§ããã奜ãŸããæäžéã¯ãåã 人ããã®äœ
éããã®èæ§ãæé床ã«ãã倧ããå€ããããã
ãŠã±ãŒã¹ããšã«å»è ã«ãã確å®ãããã°ãªããª
ããåè¿°ãããéã¯èšåºçµéšã«åŸããã®ã§ããã
ã«ããææã®ç¡é£æ¬²èªçºããã³äœéã³ã³ãããŒã«
ããã³ïŒãŸãã¯æžéå¹æãé·æã®æ²»çã«ãã€ãŠé
æããããã®é·ææ²»çã¯é£æ¬²æ¬ ä¹èæ§ã®çºçãæ²»
çåäœã®åŽã«ã¯èµ·ããããšãªãããã®é·ææ²»çã
å°ãªããšãïŒé±éããã«ã¯ïŒé±éã«ãããã€ãŠç¶
ç¶ããããããšãã§ããããšããããã«å ±åãã
ãèšåºè©Šéšã®èŠ³å¯ããæããã«ãªãã®ã§ããã èšåºè©Šéšã®åœ¢ã§ã®ä»¥äžã®æ²»çããã³äŸã¯ãäŸç€º
ãšã«ã®ã¿ç€ºããããã®ã§ãéå®çã«èŠããããã®
ã§ã¯ãªãã ããšã¢ãã»ãã³ã¿ãã¬ããã®èª¿è£œ 代衚çãªåäœåŸåæäžåœ¢æ ã¯ã以äžã®çµæã§ã
ãã MG ïŒ ããšã¢ãã»ãã³é žä»å å¡©ã奜ãŸããã¯å¡©é žå¡©
100.0 ïŒ ã©ã¯ããŒã¹ 126.0 ïŒ ã»ã«ããŒã¹ ïŒãã€ã¯ãã¯ãªã¹ã¿ãªã³ïŒ 54.0 ïŒ ããªãããã ïŒTMâãããã³USPXXïŒ 10.0 ïŒ ã°ãªã»ãªã³ïŒ85ïŒ ïŒ 4.9 ïŒ ã¹ãã¢ãªã³é žãã°ãã·ãŠã 3.2 ïŒ ã¿ã«ã¯ 34.1 ïŒ ãµãã«ãªã³ 78.1 ïŒ äºé žåãã¿ã³ïŒCI77891ïŒ 0.9 10 ãŒã©ãã³ 0.1 11 ã°ãªã³ãŒã¹ïŒæ¶²ç¶ïŒ 0.6 12 ã¢ã«ã·ã¢ã¬ã 4.0 13 ãŠãŒãã©ã®ãã ïŒTMâããªã¢ã¯ãªã¬ãŒãæš¹èïŒ 3.8 代衚çãªã¿ãã¬ããã®èª¿è£œæ¹æ³ã¯ã以äžã®åŠã
ãšãªããã äžèšïŒãïŒãå®å šã«æ··åããäžèšïŒããã³ïŒã®
ã¢ã«ã³ãŒã«æ§æ°Žã®æ°Žæº¶æ¶²ã§åŸ®çŽ°åãããåŸããã
也ç¥ç²æ«ã¯ãäžèšïŒããã³ïŒãšæ··åããããåã
320mgã®ã¿ãã¬ããã®åœ¢ã«å å§ããããšãã¿ãã¬
ããã¯äžèšïŒã12ãšãšãã«ç³è¡£åŠçããããããŠ
ææãªãã°äžèš13ãšã®è žçšã®ã³ãŒãã€ã³ã°ããã
ãããã®çµæã®ã¿ãã¬ããã¯èšåºãã¹ãã«äŸãã
以äžã®ããšãçµæãäžããŠããã ä»ã«ãé瀺ããããã«ããšã¢ãã»ãã³ãŸãã¯ã
ã®è¬å€çã«å容ãåŸãå¡©ãæå¹ãªç¡é£æ¬²èªçºæ§é
å«æããåäœæäžåœ¢æ ã¯å€æ°èª¿è£œãããããè¬å€
çãŸãå»åŠçæè¡ã®ç¢ºç«ãããæ¹æ³ã«åŸãåæ§ã®
æ§èœã瀺ãã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒãã®ç 究ã¯21ã®äžè¬çéæ¥å»ã«ããã
ã«ãã»ã³ã¿ãŒã»ããã«ã»ãã©ã€ã³ãã»ã°ã«ãŒ
ãã»æ¯èŒèŒç 究ã®åœ¢ã§ããšã¢ãã»ãã³ïŒãã®èš
åºè©Šéšã§ã¯å¡©é žå¡©ã®åœ¢ã§çšããããïŒããã³åœ
è¬ïŒPlaceboïŒãçšããŠè¡ã€ãã å ¬ç¥ã®ãããããã»ã¹ã±ãŒã«ïŒNatvig
scaleïŒïŒãªã¹ãã1956ïŒã«ãã20ã60ïŒ éå°äœ
éã®è¥æºæ£è ã16é±éã®æ²»çæéã®éïŒé±éã
ãšã«äœé枬å®ãããã åéæ¥å»ã¯ïŒäººã®æ£è æ²»ççšã«ã¿ãã¬ããïŒ
ç®±ãåãåã€ããïŒç®±ã¯åœè¬ã®ãã®ã§ãããæ®
ãã®ïŒç®±ãããšã¢ãã»ãã³ã¿ãã¬ãããå«ãã
ãã®ã§ããïŒã¿ãã¬ããã¯äžè¿°ã®èª¿è£œæ³ã§åŸã
ãããã®ã§ãããããšã¢ãã»ãã³å¡©é žå¡©100mg
ãå«æãããã®ã§ãããïŒ æäžéïŒããšã¢ãã»ãã³ã®æäžæ¥éã¯ã第ïŒé±ã¯
100ïŒ200mgããã®åŸã®æ²»çæé200ïŒ200mgã§ã
ã€ãã é£é€æéïŒå ±éã®é£åçš®ã®ã«ããªãŒäŸ¡ã®è¡šã¯åæ£
è ã«é åžãããããåèšãšãã«ã®ãŒæåã®æ倧
å€ã«é¢ããé£é€å¶éã¯èŠæ±ããªãã€ãã çµæïŒ ïŒ æ£è è³æ 21ã®äžè¬éæ¥å»ã¯ãè©Šéšãéè¡ããåã å¹³å
ããŠïŒãïŒäººã®æ£è ãæ²»çããã 74人ã®æ£è ã®ãã¡44人ã16é±ã®æ²»çæéãé
ããããåœè¬35人ã®ãã¡24人ãããšã¢ãã»ãã³
39人ã®ãã¡20人ã ããšã¢ãã»ãã³ã§ã®æ²»çã§ïŒäººã®æ£è ã®ã¿ã
å¯äœçšã«ããè©Šéšããå€ãããã ïŒ äœéæžé 16é±éã®æ²»çåŸã®äºã€ã®ã°ã«ãŒãã®æ£è ã«ã
ã€ãŠç€ºãããäœéæžéã®çµæã¯ãå¹³åã®äœéæž
ãç¡è¬å¹ããšã¢ãã»ãã³ã§ã®16é±éæ²»çåŸãã
ãã2.2Kgãš6.0Kgã§ãã€ããã¹ããŠãŒãã³ãã®
ïœâãã¹ããçšããããšã«ããããã®äºã€ã®ã°
ã«ãŒãã®å·®ã¯ãŒããšã¯çžç°ããŠããïŒïŒ°âå€ïŒ
0.02ïŒã ïŒã€ã®æ£è ã°ã«ãŒãããåŸãããäœéæžéã®
æéççµéããããããããïŒäœéå€åãšæé
ãšã§ïŒãã°ã©ãããäœéã®ããã«æžéããããš
ããã®ããšã¢ãã»ãã³æ²»çã16é±é以äžç¶ããŠ
ãããšãæåŸ ãããããšã瀺ãããã 16é±éåœè¬ãšããšã¢ãã»ãã³ãšã§æ²»çããŠåŸ
ãããäœéæžéã®çšåºŠã«ãã€ãŠæ£è ã®ååžãã
ãããããïŒäœéå€å察æ£è æ°ïŒãäœéå€åã®
å¹ ã¯ãåœè¬æ²»çãšæ¯ã¹ããšã¢ãã»ãã³æ²»çã«ã
ãå Žåã®æ³ãããªãçããã®ã§ãã€ãã çµè«ïŒããšã¢ãã»ãã³ã®éåžžã®æ¹æ³ã§è¥æºæ£è ãž
ã®16é±éã®æäžæ¥é400mgã®æœçšã¯é¡èãªäœé
æžéãããããããªãã¡åœè¬ã®æ£è ã§å¹³åäœé
æžé2.2Kgã§ããã®ã«å¯Ÿããå¹³åäœéæžé6.0Kg
ã§ããã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒãã®èšåºè©Šéšã§ã¯ãããšã¢ãã»ãã³ã¯
13人ã®è¥æºå©Šäººã«ãããŠãã®äœéæžéå¹æãç
究ããããããšã¢ãã»ãã³ã¯ïŒé±ãã16é±éãŸ
ã§æäžæ¥é300mgã§æœçšãããã13人ã®ãã¡ïŒ
人ã®å©Šäººã¯æ²»çã«ããäœéãæžå°ãããã®æžå°
éã¯0.2ãã8.5Kgã§å¹³åæžé2.8Kgã§ãã€ãã ïŒâHTæžéã®çšåºŠãšäœéæžéãšã®éã®çžé¢
é¢ä¿ã¯åŸãããªãã€ãã æ£è ãšæ¹æ³ïŒããšã¢ãã»ãã³ã¯ãå ¬éç 究ã«ãã
ãŠã®æäžæ¥é300mgïŒæ100mgãååŸ200mgïŒã
è¥æºãã婊人ã«æœçšãããã 圌女ãã¯æåã®ïŒã±æã¯ïŒé±éããšã«äœéã
枬å®ãããããããåŸã¯ïŒé±éããšã«è¡ãªãã
ãã枬å®ããšã«è¡æ¶²ãµã³ãã«ããšãããã©ãºã
äžã®ããšã¢ãã»ãã³ããã³å šè¡æ¶²äžã®ïŒâHT
ã枬å®ããããè¡æ¶²ãµã³ãã«ã¯æã«åæ¥ã®æäž
ãã14ã16æéåŸã«æ¡åããããããšã¢ãã»ã
ã³ã®æ¿åºŠã¯ãã¬ã¹ã¯ãããã°ã©ãã€ã«ãã枬å®
ããããBeckgaardããã³LundãJ.
Chromatgrã133ã147ã152ïŒ1977ïŒïŒ
BeckgaardããAnal.Chim.ActaïŒ99ïŒ189â
192ïŒ1987ïŒããïŒâHT枬å®ã¯Squircsã®æ¹æ³
ïŒGournal of Neu rochemistry 1975ã24ã
47ïŒã®å€æŽãçšããŠè¡ãªãããã èèªéå€çã®æ²»çãåžæããããå åæ³æµ®äž
ã®ãŸãã¯ä»ã®éãç æ°ãæããªã婊人ã¯ãã€ã
ãããè©Šéšãåããããšãèš±ãããã49ãã69
æã®ã°ã«ãŒãã®13人ã®å©Šäººã16é±éã®ã¿ã§æ²»ç
ãã¹ã¿ãŒãããèèªéå€çãšã¯å¥ã«ïŒäººãé€ã
ãŠå šãŠã®æ£è ã¯äžŠè¡ãã身äœçãªç æ°ãæããª
ãã€ããïŒäººã¯çæ£ç³å°¿ç ã§ãããããïŒäººã¯
å ããªéææ§ã§ãã€ãã å šãŠã®äººãäœå¹Žã®éè¥æºãããŸãŸã§ããã以
åå»åŠçæ瀺ã®äžã«é£äºçæ³ãè©Šã¿ããæåã
ãªãã€ãã®ã§ããã ãããã®æ£è ã®äœéã®å¹³åã¯ç 究ã®éå§æ
83.2Kgã§ã€ããèèªæ§ã®çšåºŠã¯ãçæ³äœé
ïŒNatvigã1956ïŒãè¶ããããŒã»ã³ãã§ç€ºãã
ãããã®ããŒã»ã³ãã¯16ãã111ãŸã§çµããã
ã®ã§å¹³å41ã§ãã€ãã婊人ãã¡ã¯æ²»çæéäžå¶
éãããé£äºãããããã«ã¯ããããŠããªãã çµæïŒ13人ã®ãã¡ïŒäººã®å©Šäººã0.2ãã8.5ïŒå¹³å
2.8KgïŒã®äœéæžãšãªã€ããïŒäººã®æ£è ã®äœé
ã¯å€ãããïŒäººã¯0.4ã2.0Kgå¢å ãããïŒé±é
以äžæ²»çãããæ£è ã«ãšã€ãŠæ²»çæéã®äœéå€
åã«ã€ããŠã¯ãå°ããšãïŒäººã®æ£è ã«ãããŠã
äœéæžã¯10ãã16é±ãŸã§ã®éç¶ç¶ããã å šè¡æ¶²äžã®ïŒâHTæ¿åºŠã¯ãïŒé±éæ²»çã®çµ
ãã«ã¯0.14ãã0.05ÎŒïœ/mlã®å¹³åå€ã«ãŸã§æž
å°ããã16é±éã®æ²»çã®ã®ã¡ãïŒâHTæ¿åºŠã¯
ãŸã 0.05ÎŒïœ/mlã§ãã€ããïŒâHTæžå°ã®çšåºŠ
ãšäœéæžå°ãšã®éã®çžé¢é¢ä¿ã¯åŸãããªãã€
ããè¥æºåºŠã®çšåºŠãšäœéæžå°ãšã®çžé¢é¢ä¿ãåŸ
ãããªãã€ãã å¯äœçšïŒå¯äœçšã¯ïŒäººã®æ£è ã«èªãããããïŒäºº
ã¯å£å 也ç¥ãšãªã€ãããã®ã±ãŒã¹ã¯ãã¹ãŠãã
ããã§äžæçã®ãã®ã§æ²»çãç¶ããããšã§æ¶ã
ããïŒäººã¯ãïŒé±éã®æ²»çåŸåœå䟿ç§ãšãªãã
æ¶åäžè¯çããã«æ²»çãäžæ¢ãããïŒäººã®æ£è
ã«ã¯é£æ¬²æ¬ ä¹çå¹æãåœåèªããããã ããããã¢ãŠãïŒïŒäººã®å©Šäººã¯ããšã¢ãã»ãã³ãš
ã¯é¢ä¿ãªãçç±ã§æ²»çãäžæ¢ããããããã®ã
ã¡ïŒäººã¯å€èŠ³ã¯å€ãããïŒäººã¯ïŒé±éåŸãªãã
äœéãæžããªãã®ã§æ²»çäžæ¢ãåžæãããïŒäºº
ã¯åé¡ãå€ãæ²»çã¯å®éçãªçç±ã§å»åž«ã«ãã
äžæ¢ããããæåŸã®æ£è ã¯æ²»çãããŠããªãé
ææ§ã®å»åŠçæ²»çã®ããã«ããšã¢ãã»ãã³æ²»ç
ããå€ãããã ããšã¢ãã»ãã³ïŒäžè¬ã«å®å®ç¶æ è¡ãããã®ããš
ã¢ãã»ãã³æ¿åºŠã¯ãåæéçïŒïŒnïœ/mlïŒä»¥
äžã§ãã€ããïŒäººã®å©Šäººã ãã枬å®ãããæ°å€
ã§ãããå®å®ç¶æ ã®æé«ã®æ¿åºŠã30nïœ/mlã§
ãã€ãã èšè«ïŒãã®ç 究ã¯ãããšã¢ãã»ãã³ãæã«ãããª
ãè¥æºæ§ã®å©Šäººã®äœéãæžå°ãããã®ã«æå¹ã§
ããããšãæããã«ãããäœéæžå°ã¯ãè¬ãäž
ããããŠããéãç¶æããå¯äœçšã¯ãã ããã§
äžæçã§ãã€ãã èšåºè©Šéš ïŒ äžèšãšåæ§ã«ããŠãïŒäººã®è¥æºå¥³æ§ãããšã¢ã
ã»ãã³ãæ¥é600mgã§æ²»çããïŒé±éåŸå¹³åïŒKg
ã®äœéæžãïŒé±éã§4.5KgãïŒé±éã§7.5Kgã10é±
éã§11Kgã13é±éã§13Kgã20é±éã§14Kgã28é±é
ã§16Kgã36é±éã§19Kgã44é±éã§22.8Kgæžãšãªã€
ããïŒïŒäººã®æ£è ã¯18KgæžããïŒäººã¯27.6Kgãå¹³
åã§ã¯22.8Kgã§ãã€ããïŒ èšåºè©Šéš ïŒ æ ¢æ§çè¥æºæ£è ã«ãããé£æ¬²ããã³äœéã³ã³ã
ããŒã« ãã¶ã€ã³ïŒè©Šéšã¯äºã€ã®å»é¢ã§ããšã¢ãã»ãã³ãš
åœè¬ãšã®ããã«ãã©ã€ã³ãã»ã°ã«ãŒãæ¯èŒç 究
ãšããŠèšç»ãããã è¥æºæ£è ã®äœéã¯æ£è ãæ²»çãã¹ã¿ãŒããã
åã«æž¬å®ãããæ²»çïŒé±éåŸããã®åŸã¯ïŒé±é
ããšã«17é±éã®æ²»çæé枬å®ãããã é£æã®éãšçµæã¯æ²»çéå§åã«ãããæ£è ã«
ãããŸãé£é€å©å€ã«ããè©äŸ¡ããããç 究æé
ã«ãïŒåºŠè©äŸ¡ãããã èªç±ãªé£é€èš±å¯ïŒæ£è ã¯ããããé£æã«ã€ããŠå¶
éãããããéžæããããèªç±ãªé£é€èš±å¯ãäž
ããããã é£äºäžã®å¶éããªããè¡ãªããªãç®çã¯ãã
ãšã¢ãã»ãã³æ²»çã®éé£äºæåèŠçŽ ã®èªç¶ãªå€
æŽãè¡ãªãããŠäœéæžéãã§ããããã«ããã
ãã§ããã å 容åºæºïŒãããã€ããã»ã¹ã±ãŒã«ã®çæ³äœéã«
察ãã20ã95ïŒ ééã§ããã20ãã70æã®å¹Žä»£
ã®æ£è ãè©Šéšãåããã æ£è ã¯äºã€ã®éšéã§ã®å€æ¥æ£è å»é¢ã«å®åžžç
ã«å¯Ÿå¿ããããããããŸãã¯é£æ¬²æ¬ ä¹è¬ãé£é€
æéãªããé£é€å¶éãªã©ãçšããŠäœéæžéã以
åè©Šã¿ãŠããŠå»é¢ã«ãã§ã«æ £ããŠãããã®ã§ã
ã€ãã æäžéïŒïŒé±éã¯æ¥éïŒã¿ãã¬ãããïŒåãåœè¬
ãšããšã¢ãã»ãã³ã®ã¿ãã¬ãã100mgã®æäžé
ã§ããã®åŸæ²»çæéäžïŒã¿ãã¬ãããïŒåã®æ¥
éã§ãã€ããä»ã®å»çåŠçã¯ç 究ã®éãªãããª
ãã€ãã é£æã®éãšè³ªïŒïŒé±éæ¯æ¥æ¶è²»ãããå šãŠã®é£æ
åçš®ã®å³å¯ãªèšé²ãåé ç®ããšã«åã«è¡ãªã
ããïŒã±æå»çæéã¯ïŒåè¡ãªããããæ¯æ¥ã®
é£äºèšé²ã¯ããã«åæãããïŒäººã®å°éã®é£é€
çæ³æè¡åž«ã«ããåé¡ããã³ã³ããŠãŒã¿ããã°
ã©ã ãïŒCAMPâã·ã¹ãã ã»ãã³ããŒã¯ç é¢å
äŒDanish Hospital InstituteïŒãã«å ¥ããã
ããããã¯ãšãã«ã®ãŒãããã±ã質çæ°Žåç©ã
ãã³èèªå«éãçŸåšã®ãã³ããŒã¯ã®ã¡ããŠãŒã®
600ã®ããããã®é£ææ¯ã«ã€ããŠæ å ±åããã
ã®ãå«ãã§ããã çµæïŒ ïŒ æ£è è³æ 111ã®æ£è ã®ãã¡73人ã17é±éã®æ²»çãå®äº
ããã ïŒäººã®æ£è ã¯å¯äœçšã«ããè©Šéšããå€ããã
ãã19人ã¯å€èŠ³äžå€ãªããå¹ææ¬ ä¹ã®ããäžæ¢
ããããããã®æ£è ã¯ãè©Šéšèšç»ã§åã«è¿°ã¹ã
ããæé€åºæºã«ããä»ã®æ£è ãšãšãã«åæãã
ã®ããå€ãããã æ§å¥ã幎霢ãäœééé床ã蚺çæã«ããæ£è
ã®ååžã¯äžèŠ§è¡šã«ãŸãšãããããååžã¯äºã€ã®
ã°ã«ãŒãã«æ¯èŒãããã åæã«äŸããã73人ã®æ£è ã®47人ã¯ãè©Šéšã«
å ¥ã€ããšãã¯ãããŠäºã€ã®èšºçæã«ãŸãããã
ãã®ã§ãããæ®ãã®26人ã¯å šãŠãã§ã«äœéæžé
ã®è©Šã¿ã蚺çæã§åããŠãããæ¬è©Šéšã®åïŒã±
æã®éã«â12KgããïŒïŒKgã®ç¯å²ã§äœéå€åã
ãã€ããã®ã§ãã€ãã ïŒ äœéå€å 17é±éã®ããšã¢ãã»ãã³ã§ã®æ²»çã®ã®ã¡ãã
äœéã«å€åããªãã€ããäœéå€åã®ã®å¹³åå€ã¯
0.06Kgããã®ç¯å²ã¯â9.4ããïŒ7.8Kgã§ããã
åœè¬ã§ã®æ¯èŒçµæã§ã¯ãå¹³å1.6Kgã®äœéå¢ã§
ãã€ãããã®äºã€ã®èšºçæããåŸãããçµæã§
ã¯å®è³ªçãªå·®ã¯ãªãã€ãã äºã€ã®æ²»çã°ã«ãŒãã«ãã€ãŠããããäœéå€
åã®æéçµéãå³ç€ºããããæ²»çã®åæã§ããŸ
ãã¯æ²»çã®æéäžã®ã©ã®æç¹ã§ãäœéæžå°ã¯ç®
ç«ã€ãŠããªãã æ²»ç17é±éåŸã«åŸãããäœéå€åã®çšåºŠã§ã®
æ£è ã®ååžãå³ç€ºããããŠããšã¢ãã»ãã³æ²»ç
æ£è ã«å¯ŸããããããŠå¹³ååããååžãšã»ãšã
ã©äœéå¢å ã®ãªãããšã瀺ãããã 11人ã®æ£è ãããšã¢ãã»ãã³æœçšäžã«äœé
3.0Kg以äžã®æžéã§ãããïŒäººã®ã¿ãåœè¬ã§ã
ã®ãããªäœéæžãããããããã®11人ã®ããšã¢
ãã»ãã³æ£è ã®æ€æ»ã§å¹Žéœ¢ãäœééé床ã®ç¹å¥
ã®ååžã瀺ããããšããããšããªãã€ãã ïŒ ãšãã«ã®ãŒæåããã³ããã±ã質ãèèªãã
ã³çæ°Žåç©æåç 究æéäžãé£ææåã®å€åã¯
ã¿ãããŠããªããåèšãšãã«ã®ãŒæåãããã°
ã質ãèèªããã³çæ°Žåç©ã§ïŒé±éã§æ¶è²»ãã
ãéã¯ããããŠä»¥åããŸãæ²»çæéäžãã»ãŒå
ãã§ãã€ãã çµè«ïŒãã®ç 究ã®åã«ãïŒåã®ïŒã®æ£è ã¯é£é€å¶
éãæã«ã¯è¬å€ãçšããæ²»çã䜵çšããŠäœéæž
éã®è©Šã¿ãããŠèšºçæã«ã¯æ £ããŠãããããã
ã€ãŠãèªç±ãªé£é€èš±å¯ã§ã®ãã®åŸã®è¬å€è©Šéšã§
ã¯ãã®ãããªæ£è ã«ãšã€ãŠäœéæžå°ããããã
ã®ã¯å°é£ã§ãã€ããããããªããããããé£æ¬²
ããã³äœéã³ã³ãããŒã«ã¯èªããããã ãã®ç 究ãã¶ã€ã³ãããã¯é£é€å¶éããªãã
è·ããŠããªããããã®ç®çã¯ããšã¢ãã»ãã³æ²»
çã®éãé£äºæåã®æåã®èªç¶ãªå€åãšã®é¢é£
ã§äœéæžå°ããã³ïŒãŸãã¯ã³ã³ãããŒã«ãæ±ã
ãããšã§ãããåèšãšãã«ã®ãŒæåã®äžå€ãªã
ãæžå°ã«ãããããã€ã³éã®å¢å ãæåŸ ããã
ã®ã§ããããšãã«ã®ãŒã®ïŒæåãŸãã¯åèšãšã
ã«ã®ãŒæåã®å€åã¯ãªããç 究äžèªããããªã
ã€ããããã®ããäœéæžéãèªããããªãã€ã
ã®ã§ããã èšåºè©Šéš ïŒ 20ïŒ ä»¥äžã®äœéééã®å€æ¥æ£è 21人ãã¹ãŠã«å¯Ÿ
ã300ã400mgã®æäžæ¥éããšã¢ãã»ãã³ãæœçšã
ãããäœéééã®å¹³åã¯41ïŒ ã§ãã€ãã16人ã®æ£
è ã¯12é±éã®æ²»çãåããïŒäººã¯ïŒãïŒé±ã®ééš
åçãªæ²»çã®ã®ã¡äžæ¢ãããããã¯ãã¹ãŠè¬å€æ²»
çç¶äžã®åå ã®ããã§ã¯ãªãã45æãŸã§ã®è¥å¹Žæ£
è ã¯45æ以äžã®ã°ã«ãŒãã«æ¯ã¹ãäºæ³ã©ãããšã
ã«ã®ãŒæåãé«ãç©çç掻æ§ãããé«ãã¬ãã«ã§
ããããšãç¹åŸŽã§ãã€ãã 20人ã®æ£è ãäœéãæžããå¹³åã®äœéæžã¯3.1
Kgã§ãã€ãããã倧ããªäœéæžå°ã¯è¥å¹Žã°ã«ãŒã
ã®æ£è ã«èªãããããå€æ¥æ£è ã®12é±éã®æ²»çã
åãã16人ã®å¹³åäœéæžéã¯ãè¥å¹Žã°ã«ãŒãã§
4.8KgïŒïœïŒïŒãs.d.ïŒ2.5ïŒãäžæ¹è幎ã°ã«ãŒãã®
ããã¯2.2KgïŒïœïŒïŒãs.d.ïŒ1.2ïŒã§ãã€ããã
ã®äºã€ã®å¹Žéœ¢ã°ã«ãŒãéã®äœéæžéã«ãããå·®ã¯
éèŠã§ããã察ã«ãªã€ãŠããªãå€ã«å¯Ÿããã¹ããŠ
ãŒãã³ãã®ïœâãã¹ãã¯ïŒ°âå€ã0.02ã§ãã€ãã
ãã®äºã€ã®å¹Žéœ¢ã°ã«ãŒãããããã«å¯Ÿããäœéæž
å°ã®æéçµéãå³ç€ºããããã€ãã®å€åãæãã
ã«ããããè©Šéšã§ã®å šãŠã®ç¹ã§ã45æããäžã®ã°
ã«ãŒãã§ã®äœéå€åã¯45æ以äžã®ã°ã«ãŒãã«ãã
ããã倧ãããäŸãã°ïŒé±éã§ã¯ã45æ以äžã®ã°
ã«ãŒãã®å¹³åäœéæžéã¯1.5Kgããšããã45æ以
äžã®ã°ã«ãŒãã§ã¯2.5Kgã§ãã€ããïŒé±ç®ããã
ãïŒKgãš3.5Kgã10é±ç®ããããïŒKgãããåäž
åã€ãã®ãšïŒKgããããŠ12é±ç®ã®çµãã§ã¯ããã
ã2.5Kgã®äœéæžãšã»ãŒïŒKgã§ãã€ãã èšåºçè©Šéšã§ã®ç æŽã¯æ£è ãžã®ã¢ããã€ã¹ãå ¥
ã€ãŠãããé£é€å¶éã¯äžå¿ èŠã§ããããšãé£é€ç¿
æ £ãå€ããå¿ èŠãªãããšã平垞ã©ããã®é£ç©ããš
ãããã«ããããŠç©ºè ¹ãšæºè ¹ã«åŸã€ãŠé£é€ã®éã
決ããããã«ãšèšãããŠãããïŒãïŒã®å¯äœçšã
å ±åãããã ãã§ãïŒäººã®æ£è ãå£å 也ç¥ã§äžæº
ã蚎ããåãæ°ã蚎ãããããããã®äžèª¿ã¯ãã¹
ãŠãã ããã§åŸŽåãããã«æ²»çãããŠãããã¡ã«
æ¶ãããïŒäººã®æ£è ãé çã®é®éã瀺ãããè¡æ¶²
åçãèèããã³è èæ©èœã®å®éšå®€ã§ã®èŠ³å¯ã§ã¯
æ²»çäžãªããç®ç«ã€ãå€åã¯ãªãã€ããECGã¢
ãã¿ãŒã¯å šæ£è ã«ã€ããŠæ²»çã®åããã®æéãã
ã®åŸæ£åžžã®ãã¿ãŒã³ã瀺ããã ãã®è©Šéšã§ãå šè¡æ¶²äžã®ïŒâHTæ¿åºŠã®æ倧æž
å°ã¯0.07ÎŒïœ/mlã®å€ããïŒé±éã®æ²»çæéåŸç€º
ãããæ²»ççµäºåŸïŒé±éã§ãïŒâHTæ¿åºŠã®å¹³å
ã¯0.14ÎŒïœ/mlãšãªããæ£åžžã®ïŒâHTã¬ãã«ã«å
埩ã瀺ãããããšã¢ãã»ãã³ã®å®å®ç¶æ æ¿åºŠã¯å š
ãŠæ¥µããŠäœãã€ãããã ïŒäººã®æ£è ã®ã¿è¡ããã
æ¿åºŠãåæé床ã®ïŒnïœ/mlãè¶ãããã®æ£è ã«
察ããå®å®ç¶æ æ¿åºŠãïŒãš20nïœ/mlã®éã§å€å
ãããããšã¢ãã»ãã³ã®ããããŠäœãå®å®ç¶æ æ¿
床ãšé¢ä¿ãªããå šè¡æ¶²äžã®ïŒâHTã¯æ²»çäžåŒ·åºŠ
ã«æžå°ããããšã¢ãã»ãã³ãããããŠäœæ¿åºŠã§ã¯
è¡å°æ¿ãžã®ïŒâHTæåã®åŠšããããããšã瀺ã
ãããCNSâåºæ¿è¬å¹æã¯èšåºè©Šéšã®éãªãã
èŠãããªãã€ãã ãã®èšåºè©Šéšã®çµæãããšã¢ãã»ãã³ã¯12é±é
ã®æ²»çæéã«ãããè¥æºããããæ£è ã§ã®é£æ¬²ã
ãã³äœéã®ã³ã³ãããŒã«ããã³æžå°ã«å©ããããš
ã瀺ãããã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒããšã¢ãã»ãã³ãšåœè¬ãšã®ããã«ã»ã
ã©ã€ã³ãã»ã°ã«ãŒãæ¯èŒç 究ã§äºãå å ¥ããŠã
ãè¥æºæ£è ã«ã€ããŠè¿œè·¡ç 究ããªããããäžèš
ã®ç 究ã®çµæã¯ãããã¯ã³ãã³ããŒã²ã³ã®äºã€
ã®å€æ¥æ£è 蚺çæã§è¡ãªããããã®ã§ãããã
äžèšèšåºè©ŠéšïŒã§ãããŸã§ã«ãã§ã«å ±åããã
ãã®ã§ããã æ¹æ³ïŒããã«ã»ãã©ã€ã³ãç 究ã§ã®17é±éã®æ²»ç
çµäºåŸããã®äºã€ã®èšºçæã®äžã€ã®æ£è å šå¡ã
ããšã¢ãã»ãã³æ²»çãåãããããŸãã¯ç¶ç¶ã
ãããéããããã ãã®ç 究ã®çŽåã®æ²»çæéã«ãããŠèªç±ãªé£
é€ã®èš±å¯ãæ¯æããã®ãšã¯å察ã«ãä»åºŠã¯æ£è
ã®é£äºã®ã¢ããã€ã¹ãåããã圌çã¯çŽ5000ã
ããžãŠãŒã«ãžã®é£é€äžã®å¶éããã³é£æ¬²æ¬ ä¹æ²»
çãçµã³ã€ããäœéæžå°ããã°ã©ã ã®å©ç¹ã«ã€
ããŠèª¬æãåãããããããã»ãã«ã¯ãã©ããª
é£é€å¶éãè¡ãªãããã決å®ããããã³ã³ãã
ãŒã«ãããããè©Šã¿ã¯ãªãããªãã€ãã ããšã¢ãã»ãã³ã®æäžæ¥éã¯600mgã§ãã€
ããæ£è ã¯ãæïŒåäœé枬å®ãšå®éšå®€çã³ã³ã
ããŒã«ã®ãã蚺çæã蚪ãããæ£è ã¯æé«ïŒã±
æéããšã¢ãã»ãã³ãæäŸãããã çµæïŒããã«ã»ãã©ã€ã³ãè©Šéšãçµãã35人æ£è
ã®ãã¡ã28人ã¯ïŒé±é以äžã«ãããããšã¢ãã»
ãã³ã§ã®æ²»çãåããã10人ã®æ£è ããã®çŽå
ãŸã§17é±éã®éããšã¢ãã»ãã³ã§ã®æ²»çãåã
ãŠãããã18人ã®æ£è ã¯ç¡è¬å¹ç©ãåããŠã
ãã åŸãããå¹³åã®äœéæžéã¯16é±ã®æ²»çæéåŸ
ã§5.2KgïŒSDïŒ5.5ãïœïŒ28ïŒã§ãã€ãã ããšã¢ãã»ãã³ã§åŸåããæ²»çãåããŠãã
æ£è ã«å¯ŸããŠã¯ãå¹³åäœéæžéã¯2.1Kgãäžæ¹
ç¡è¬å¹ç©ã§äºãæ²»çãããŠããæ£è ã®ãã®ã¯
6.9Kgã§ãã€ãã æ²»çæéäžåŸãããäœéæžéã®çšåºŠã¯è¡šã«ã
ããå³ç€ºãããäžè¿°ããçµæã確ãããããã ïŒäººã®æ£è ã«ã€ããŠã¯ã10Kg以äžã®äœéã芳
å¯ãããã圌çã¯å¹³åæé21é±éã®è©Šéšäžã«å¹³
å13.6Kgæžéããã 11人ã®æ£è ã¯ãïŒã±æéããšã¢ãã»ãã³ãå
ããããã®ç 究ã®çŽåããã«ã»ãã©ã€ã³ãç 究
ã§17é±éæ²»çæéãçµãŠããããšã«ããã圌ç
ã¯æ²»çãïŒã±æããããšã«ãªã€ããïŒã±æã®æ²»
çåŸã«10Kgã®å¹³åäœéæžãšãªããŸã§ã®äœéå€å
ã®çµæãå³ç€ºããè©Šéšã«ãããã€ã11人ã®æ£è
ã«ããããã®æ³šç®ãã¹ãäœéæžããã©ããã€ã
ã¯ã«é瀺ãããã è°è«ïŒèªç±ãªé£é€èš±å¯ã€ãã§ã®ããã«ã»ãã©ã€ã³
ãç 究ã®ããã ãããšã¢ãã»ãã³ãåœè¬ã°ã«ãŒ
ãããªããèããäœéæžå°ãèªããããªãã€
ããããšã¢ãã»ãã³ã§æ²»çãããæ£è ã¯å¹³å
0.5Kgæžããäžæ¹åœè¬ã°ã«ãŒãã¯1.1Kgã®äœéæž
ãšããé¡èæ§ãèŠããããäœéæžã®æé«ã¯åã¯
åœè¬ã§æ²»çãããæ£è ã«ãã€ãŠåŸãããã è¥æºæ£è ã«ãããŠã¯ããããšã³ãã«ãã³ãã
ãšã³ã¡ãã©ãžã³ããã³ããšã³ãã«ã©ãã³ãåã
ãŠåæ§ã«ãã¶ã€ã³ãããè©Šéšãšé¡åçæ¯èŒã«ã
ããŠãããšã³ãã«ã©ãã³ã®ã¿ã12é±é以äžæå¹
ã«äœéæžããããããŠãããïŒPinderãR.M.
ãïŒããšã³ãã«ã©ãã³ïŒãã®è¬çåŠçæ§è³ªãã
ã³è¥æºæ§ãžã®æ²»çç¶ã®å¹æãDrugs 1975ã10
ïŒïŒïŒã241ã323é ïŒãããããæ²»çã®ã¯ããã®
ïŒé±éã§ããšã³ãã«ã©ãã³ãèæ§ãçºçããã
ãããšãå ±åãããŠãããïŒStunkardãA.SïŒ
è¥æºæ§æ²»çäžã®ããšã³ãã«ã©ãã³ãLancet
1973ãïŒã503ïŒããã®ç 究ã§ã®çµæã¯ãããšã¢
ãã»ãã³ãïŒã±æã®æ²»çåŸé£æ¬²æ¬ ä¹çµæãçºç
ãããŠããããšã瀺ãããã ããã«ãããšã¢ãã»ãã³ã¯ãåç¬ãããé£é€
æ瀺ã€ãã§äžããããæ¹ãããããšãçµè«ã§ã
ãããã¡ããèªç±ãªé£äºããããããæ£è ã«ã
ããŠãæå¹ã§ã¯ããã çŽè žãžã®æœçš ããçš®ã®çç©è¬å€åŠçç 究ã«ãããŠã¯ãæ¯æ¥ïŒ
åçŽè žçã«æœçšãããããšã¢ãã»ãã³300mgãå«
ãåäœãµã€ãºã®åº§è¬ãçµå£çã«æå¹ãªæ¯æ¥ã®æäž
éã®ããšã¢ãã»ãã³600mgãçšããŠåŸãããã®ãš
åãè¡ãããæ¿åºŠãåŸãå¹æãããããšã枬å®ã
ãããããåºããããç¯å²ãæ¡çšãããããšã«ãª
ããã50mgã®ããšã¢ãã»ãã³ãšããäœãå«éã®åº§
è¬ãçšãããã600mgãæ¥æ¯ã®çŽè žçæçšããã
ããŠå¹æçã§ããããšãã«å°ãªãåäœæäžéã«å
ãããšããããããã®è©Šéšã§ãã¹ãããã座è¬ã¯
éåžžã®è解ãããã座è¬çšããŒã¹ã«ããšã¢ãã»ã
ã³ãåäžã«åæ£ãããŠå«ãŸãããã®ã§ããã äžè¿°ã®ããšãããããæ£è ãç¹ã«è¥æºãããã
æ£è ã®é·ææ²»ççšã®æ°èŠæ¹æ³ãé£æ¬²ããã³äœéã³
ã³ãããŒã«æžå°ãç®çãšãããããŠããã«ããæ¬
çºæã®ä»å çç®çã®ãã¹ãŠãéæãããã®ã§ãã
ããæ¬çºæã«ãã€ãŠäžããããã®ã§ããã
ã³ãããŒã«ãªããæžéãèæ§ãçºçãããããšã®
ãªãé·ææ²»çããããã®æ¹æ³ã§ã®ããšã¢ãã»ãã³
ïŒfemoxetineïŒããã³ãã®å¡©ã®äœ¿çšãç¹ã«å°ãªã
ãšãïŒé±éã®æéã«ãããè¥æºããæ£è ã®æ²»çã«
ãããæ¹æ³ã«é¢ããã å€å¹Žã«ããããå€ãã®è¬å€ããç¹ã«è¥æºäººéã«
ããããã®ç¡é£æ¬²èªçºæ§ããã³äœéã³ã³ãããŒã«
ãªããæžéå¹æãšã«æ¡çšããããŸãææ¡ãããŠã
ãããããè¬å€ã¯ããŸããŸã®ã¿ã€ãã®ãã®ã§ãã€
ãã亀æç¥çµè奮æ§ã¢ãã³é¡ãæ¡çšãããŠãã
ããäžè¬çã«ã¯ãã®åŒ·ãäžæ¢ç¥çµç³»ãžã®åºæ¿çäœ
çšã«ããäžå®ãèœã¡çãã®ãªãããã³äžç çãšã
ã€ã奜ãŸãããªãå¯äœçšãæããããšãç¥ãããŠ
ãããä»ã®æ§é ãæã€ãååç©ãæ¢çŽ¢ããããé£
欲ããã³äœéã®ã³ã³ãããŒã«ãªããæžéã®ããã®
ç¡é£æ¬²èªçºè¬ãšããŠæäŸãããååç©ã®äžã§ã¯ã
ãã«ã¢ãã¬ããªã³ïŒNAïŒããã³ããŒããã³
ïŒDAïŒã®ç¥çµè§£æŸïŒneuronal releaseïŒãå¢å€§ã
ããååç©ãããããã®ãããªååç©ã¯ãæçšã§
ããããšãæ€åºãããŠããããæ£è ãäžè¬ã«åºã
䜿çšãããŠããè¬ã«å¯Ÿãèæ§ãçºçãããšããæ¬
ç¹ãæã€åŸåããããçµæãšããŠãé·æã®æ²»çã¯
ããŸããããªããããã¯ç¡é£æ¬²èªçºå¹æãæçšïŒ
é±éãªãããã以äžã§æ¶ããŠããªãåŸåãããã
ãã§ãããäœéæžéã®çµäºãããããå®éèæ§ã
çºçããæç¹ãéããŠæ²»çãç¶ããŠããã«ããã
ããã以åã«å°éããäœãã¬ãã«ããäœéå¢å ç¶
æ ãžåž°ã€ãŠããŸãã®ã§ããããããã€ãŠããã®ã
ããªååç©ã®æœåšç䜿çšã¯ãå®éã¯ã»ãšãã©å¶é
ãããŠããããªããªããé£æ¬²ããã³äœéã³ã³ãã
ãŒã«ããã³æžéããã°ã©ã ã¯ãç¹ã«è¥æºããæ£è
ã«ãããŠã¯ïŒé±éæ²»çã¹ã±ãžãŠãŒã«ãè¶ããŠãã
ã«ç¶ããã®ã奜ãŸããããã§ãããå ¥æãããã
ç¡é£æ¬²èªçºè¬ã®äžã§ã¯ãããšã³ãã«ã©ãã³
ïŒfenfluramineïŒã®ã¿ãïŒé±éãè¶ããæ²»çæé
ã«ãããç¡é£æ¬²èªçºããã³äœéæžéå¹æãæã€ã
ãã§ãããããããããšã³ãã«ã©ãã³
ïŒfenfluramineïŒã¯ãã»ãããã³ïŒïŒâHTïŒæå
é²æ¢å€ãšã¯ç°ãæ§æ ã®äœçšã«ãã€ãŠç¹åŸŽã¥ããã
ããã®ãšããŠç¥ãããå®éãã®æåã劚ããããš
ã«ãã€ãŠãããããã貯èµå ŽæããïŒâHTãæŸ
åºããåºæ¿æ§ã«ãã€ãŠäœçšãããããã€ãŠãå ¬ç¥
ã®ïŒâHTæŸåºåºæ¿æ§è¬å€ã®ããšã³ãã«ã©ãã³ã®
æ§èœã«åºã¥ãïŒâHTæåé²æ¢å€ãªããæå¶å€ã«
é¢ããŠã¯ãªããã®çµè«ã«ãéãããªãã®ã§ããã
ããšã³ãã«ã©ãã³ããŸãNAããã³DAãæŸåºãã
ããã«ãïŒâHTã®å¹æã¯éžæçãšãªããªãã çš®ã ã®ã¿ã€ãããã³æ§é ã®æ£è ãèæ§ãçºçã
ããããšã®ãªãé·æäœçšæ§ã®ç¡é£æ¬²èªçºæ§å»è¬å
åŸã®ããã®åªåããªãããŠãããããããããã
ã®çæãå®è³ªçã«åé€ããŠã¯ããªããæããã«ã
æãŸãããªãå¯äœçšã®ãªããè¥æºæ£è çšã®é£æ¬²ã
ãã³äœéã®æå¹ãªã³ã³ãããŒã«ããã³æžéã®ãã
ã®æ·»å ç©çãªãŸãæ¹è¯ãããç©è³ªããã³é·ææ²»ç
æ³ãžã®èŠæ±ãããã®ã§ããã ã©ããã«ãããæ¡é£Œæ 床ã®å€è³ªåãæžå°åã«ã
ããïŒâHTæåé²æ¢å€ã®å©çšå¯èœã«ã€ããŠã¯ã
ãžãšã€ãã€ãŒããã«ã³ãã«ïŒJ.E.BlundellïŒã«ã
ããInternational Journal of ObesityãïŒ1977
幎ïŒã®ç¬¬ïŒå·»ç¬¬15ã42é ã«å ±åãããŠããããã®
åè¡ç©ã®ã³ããŒã¯ãæ¬åºé¡ãæåºããéã«çšæã
ããŠããããã«ã³ãã«ïŒBlundellïŒããã³ã¬ã€ãµ
ã ïŒLathamïŒã¯ããã®åéã§ã®ãã®æè¡ãæ¡å€§
ããŠãæ¡é£Œæ 床ã®è¬å€çåæ±ãïŒæ€ç©æåã«å¯Ÿã
ãã»ãããã³ããã³ããŒããã³ã®åœ±é¿å¯èœæ§ããš
ããè«æããšã¹ã»ã¬ã©ãã€ãïŒS.GarattiniïŒãã
ã³ã¢ãŒã«ããµããã³ïŒR.SamaninïŒåãRaven
PressãããŠãŒãšãŒã¯çºè¡ã®ãCentral
Mechanisms of Anorectic Drugsããšããæ¬ã®
第83ã109é ã§çºè¡šããŠãããããã®ã³ããŒãçš
æãããŠããã第89ã90é ã«ã¯ãïŒæéã®æ¡é£Œã
ã¹ãäžã«æž¬å®ãããé£äºæ 床ãžã®ç¡é£æ¬²èªçºè¬ã®
äœçšã蚌æããå³ã瀺ãããçç£ç©ããšã¢ãã»ã
ã³ããã®å¡©é žå¡©ãšããŠç©è³ªFG4963ãšããŠè¡šãã
ããŠããããããã®å ±åè ãã¯ãããšã¢ãã»ãã³
ãæ£è ã®èæ§çºçãé¢åãªå¯äœçšããªããïŒé±é
以äžãã®éã®é·æã«ããã䟡å€ããç¡é£æ¬²èªçºè¬
å€ãšãªãããšã瀺åããŠã¯ããªããããã€ããšã¢
ãã»ãã³ã圌çã®å ±åããæžé¡äžã«é瀺ãããïŒ
æéã®é£äºæéãè¶ããŠç¡é£æ¬²èªçºäœçšãæãã
ããšã瀺åããŠã¯ããªãã®ã§ããã ãã¡ãããç¡é£æ¬²èªçºæ§è¬å€ã®åäžæäžã§é£æ¬²
ãšäœéã®æžå°ããããããšã¯ãã§ã«ç¥ãããŠãã
ããé£äºæåãšäœéãšã¯ããšã®ã¬ãã«ã«ããããŸ
æ»ã€ãŠããªããïŒã±æãªãããã以äžã®é·æç¶ã
ãããªéå°ã®é£äºæåãéé£äœèèªã®å¢å€§ãšãã€
ãçµå±ã®çµæã§ã®éé£ãšäœéå¢å ãšãªã€ãŠããŸã
ããšãããç¥ãããŠãããäŸãã°ããã®ããšã¯ã¢
ã³ããšã¿ãã³ã§ã確ç«ãããããšã§ããåç©ãã
ã³äººéã«ãããé£æ¬²æ¬ ä¹ããã³äœéæžå°ãçãã
ããååçè¬å€ãããŒãã«ïŒHoebelïŒããããª
ã³ã¹ãã³å€§åŠãã©ã€ããµã€ãšã³ã¹28å·»ã第77ã82
é ïŒ1981幎ïŒPergamon Pressã§æããã§ããã ïŒé±éãªããããããçæã®æ²»çã«ãããŠæ£è
ã«çºçããèæ§ããããããããªããããã€ãŠã
ã®ç¹ã§ãã®ãããªæ²»çã§ã¯äŸ¡å€ãæããªãç¡é£æ¬²
èªçºæ§è¬å€ã®äžã«ã¯ããžãšãã«ããããªã³ãã¯ã
ã«ããšã³ãã«ãã³ãããšã³ãã«ãã³ããããµã³ã
ãšã¿ãã³ããã³ããšã³ã¡ãã©ãžã³çãç¥ãããã
ããã¯ãDrugsãïŒ1975ïŒ10ïŒïŒïŒç¬¬241ã328é
ã®ç·èª¬è«æããã³åæžç¬¬271é å³ïŒã§ã°ã©ãçã«
瀺ãããããšãã§ããã ããšã¢ãã»ãã³ãåé çã®äºé²æ²»ççšãšããŠïŒ
é±éã«ãããïŒæ¥400mgæäžãããŠã瀺ãããå¯
äœçšã¯é£æ¬²ãšäœéã®æžå°ã§ãã€ããããããèæ§
ãç¡é£æ¬²èªçºã®èŠ³ç¹ã«ãããŠã¯è¡šãããŠããªã
ãããŸãè¡šãããŠãããªãã€ããšãã瀺åã¯ãªã
ã€ããããã®ãããªèæ§ãïŒé±éãªãããã以äž
ã«ãããæ²»çã¹ã±ãžãŠãŒã«ã«ãããŠè¡šãããªãã€
ããšããææããªããæã ãããšã¢ãã»ãã³ã§åŸ
ãçµæã®ããã€ãã¯ãAlimentazione
Metabolismo NutrizioneãïŒ1980ïŒãïŒã383ã«å ¬
ã«ãããŠããããã¯1980幎10æïŒâ11æ¥ããŒãã§
ã®è¥æºã«é¢ãã第ïŒåœéäŒè°ã§çºè¡šãããè«æã®
ã¢ãã¹ãã©ã¯ãã§ãããæ©ããŠã1980幎ã®ïŒæã«
åè¡ããããã®ã§ããã®äŒè°ã§ããã«æ€èšããã
ãŠãããããã®åŸçºå±ããçºè¡šããªãããŠããª
ãããã®çºè¡šã¯æ¬çºæåºé¡ããªãããæ¥ã®ïŒå¹Žä»¥
å ã§ããã å¯èœæ§ãæã€ãã¢ã¬ããã€ãã¯
ïŒthymolepticïŒãšããŠã®ããšã¢ãã»ãã³ã«é¢ãã
ä»ã®çºè¡šã¯ããEuropean Journal of
Pharmacologyã32ïŒ1975ïŒç¬¬108ã115é ããã³
ãPsychopharm acologiaãïŒBerl.ïŒ42ã21â26
ïŒ1975ïŒã«ç€ºãããŠãããããããã¯ç¡é£æ¬²èªçº
掻æ§ã«ã€ããŠèšåããŠããªãããŸããããšã¢ãã»
ãã³ãé瀺ããåºæ¬çãªç±³åœç¹èš±ç¬¬3912743å·
ïŒ1975幎10æ14æ¥çºè¡ïŒã§ããããããã¯ããšã¢
ãã»ãã³ã瀺ããŠãããææå¶å€ããã³æããŒã
ã³ãœã³æ»ç è¬å€ãšããŠã®ååç©ãšããŠã§ããã 掻æ§æå æ¬çºæã®çµæç©ã®æŽ»æ§ãªæåããã³æ¹æ³ã¯ãã
ãšã¢ãã»ãã³ã§ãããããã¯ïŒïŒïŒãã©ã³ã¹âïŒ
âãïŒïŒâã¡ããã·ããšããã·ïŒâã¡ãã«ãâïŒâã¡
ãã«âïŒâããšãã«ãããªãžã³ã§ããã以äžã®æ§
é åŒã®ãã®ã§ããããŸãã¯ãã®æ圹çã«éèŠãã
ãå¡©ãäŸãã°é žä»å å¡©ã§ããã 奜ãŸããããšã¢ãã»ãã³å¡©é žå¡©ããã³ããšã¢ã
ã»ãã³ãã³ãã«é žå¡©ã®ç©çå®æ°ã¯ä»¥äžã®åŠãã§ã
ãã èç¹ïŒâïŒ ãαãïŒïŒ  å¡©é žå¡© 187 ã191 74ã75.6ã ïŒæ°Žäžæ¿åºŠ0.05ïŒ ãã³ãã«é žå¡© 127.5ã130 88ã89.8ã ïŒ96ïŒ ãšã¿ããŒã« äžæ¿åºŠ0.05ïŒ çµå±ãæ¬çºæã¯ãè¥æºããããæ£è ã®é£æ¬²ãšäœ
éãã³ã³ãããŒã«ããã³æžéããã«è³ããæ¹æ³ã«
é¢ãããã®æ£è ã«å¯Ÿãå°ãªããšãïŒé±éã«ããã
ããšã¢ãã»ãã³ããã³ãã®è¬å€çã«å容ãããå¡©
ãããªã矀ããéžã°ããé£æ¬²æžéæ§ååç©ãæå¹
ãªé£æ¬²æžééã§çµå£çãªããçŽè žçã«æäžããã
ããšãããªããã®ã§ããããã®æ¹æ³ã§ã¯é£æ¬²æžé
æ§ååç©ã¯ãè¬å€çã«å容ããããã€ãªã€ãŒãšãš
ãã«æäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ãçµå£çã«ã¯çŽ100ã1000mgã®æ¥éã§æäžãã
ããããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©ã¯çŽ
400ã600mgã®æ¥éã§çµå£çã«æçšããããããã
ãŸããã®æ¹æ³ã§ã¯ãé£æ¬²æžéæ§ååç©ã¯çŽ100ã
300mgãå«æããçµå£çãªåäœæäžéã§äœ¿çšãã
ãããã®æ¹æ³ã§ã¯ãé£æ¬²æžéæ§ååç©ã¯ããã®çŽ
100mgãå«ãçµå£çãªåäœæäžéã§äœ¿çšãããã
ãã®æ¹æ³ã§ã¯é£æ¬²æžéååç©ã¯çŽè žçã«çŽ50ã
600mgã®æ¥éã§æäžããããããããã®æ¹æ³ã§ã¯
é£æ¬²æžéæ§ååç©ã¯ãã®çŽ50ã600mgãå«æãã
çŽè žãžã®åº§è¬ã®åœ¢ã§æäžãããããã®æ¹æ³ã§ã¯é£
欲æžéæ§ååç©ã¯ã掻æ§æåãšããŠçŽ300mgãå«
ãçŽè žãžã®åº§è¬ã®åœ¢ã§æäžãããããŸããã®æ¹æ³
ã§ã¯é£æ¬²æžéæ§ååç©ã¯ãïŒé±é以äžã®æéã«ã
ããæäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ã12é±é以äžã®æéã«ãããæäžãããããã®
æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©ã¯ïŒé±é以äžã®æéã«
ãããæ¯æ¥æäžãããããã®æ¹æ³ã§ã¯é£æ¬²æžéæ§
ååç©ã¯ãå°ãªããšã12é±éã®æéã«ãããæ¯æ¥
æäžããããç¹ã«ãã®æ¹æ³ã§ã¯é£æ¬²æžéæ§ååç©
ã¯ããšã¢ãã»ãã³ã®è¬å€çã«å容ãããå¡©ä»å ç©
ã§ããããã®çŽ100ã300mgãå«æããã¿ãã¬ãã
ã®åœ¢ã§æ¥éçŽ100ã1000mgãçµå£çã«æäžãã
ãããããŠç¹ã«ãã®æ¹æ³ã§ã¯ãã®ååç©ã¯ããšã¢
ãã»ãã³å¡©é žå¡©ã§ããã奜ãŸããæ¹æ³ã§ã¯ãã®å
åç©ããïŒé±éãªãããã以äžã®é·æã«ãããã
ã®æ²»çã«åŠããããæ£è ãé£æ¬²æ¬ ä¹æ§èæ§ãçºç
ãããããšãªãæäžãããããšããããšã§ããã ãã奜ãŸããæ æ§ãšããŠæ¬çºæã®å¥ã®èŠçŽã¯ã
æ£è ã«å¯Ÿãé£æ¬²æ¬ ä¹æ§èæ§ã®çºçããããããšãª
ããé·æçããŒã¹ã§è¥æºããããæ£è ã«ãããé£
欲ããã³äœéã³ã³ãããŒã«ããã³æžéã«å©ããæ¹
æ³ãšãªããã®ã§ãããããšã¢ãã»ãã³ããã³è¬å€
çã«å容ããããã®å¡©ãããªã矀ããéžã°ããé£
欲æžéæ§ååç©ãé·æã«ãããæå¹ãªé£æ¬²æžéã®
éã ãäžèšæ£è ã«çµå£çã«æäžããæäœããšãã
ã®ã§ããã®æ¥éã¯çŽ100ã1000mgã§ãããåäœæ
çšã®åœ¢ã§ã¯çŽ100ã300mgãå«ãããã®ã§ããã ããšã¢ãã»ãã³ããã³ãã®å¡©é¡ã®èª¿è£œ ããšã¢ãã»ãã³ããã³ãã®å¡©é¡ã¯å ¬ç¥ã®ååç©
ã§ããã1975幎10æ14æ¥çºè¡ã®ç±³åœç¹èš±ç¬¬
3912743å·ã«ä»£è¡šçã«èª¬æãããŠããããšããå ¬
ç¥ã®æ¹æ³ã§èª¿è£œãããããã®ç¹èš±ã®é瀺ã¯åèã«
瀺ãããããšã¢ãã»ãã³ã¯ä»£è¡šçã«ãã®å¡©é žå¡©ã®
圢ã§ã³ãŒãçªå·GF32ã®ããšã«ç¬¬ïŒæ¬ã®è¡šã®åºã®
第ïŒã®ååç©ãšããŠç€ºãããŠããã é žä»å å¡©ã®åœ¢ã§æ¬çºæã®æ¹æ³ãæå¹ãªååãšã
ãŠæ¡çšããã«ã¯ãé žã¯å°ãªããšãéåžžã®æ²»ççæ
çšã§æ¯æ§ã®ãªãè¬å€çã«å容ãããã¢ããªã³ãå«
ããããªãã®ãšããŠéžã°ããããã®ã°ã«ãŒãã«å«
ãããããããªä»£è¡šçãªå¡©ã¯å¡©é žå¡©ãèåæ°ŽçŽ é ž
å¡©ãç¡«é žå¡©ãé ¢é žå¡©ããªã³é žå¡©ãç¡é žå¡©ãããé ž
å¡©ïŒquinateïŒãé ç³é žå¡©ããã³ãã¬ã€ã³é žå¡©ã§ã
ããä»ã®é žä»å å¡©ãé©çšãåŸãããææã§ããã°
æ¡çšããããäŸãã°ããããŒã«é žãå®æ¯éŠé žãã¢
ã¹ã³ã«ãã³é žããã¢ã€ã³é žïŒpamoic acidïŒãã³
ãã¯é žããµãªãã«é žããã¹ã¡ãã¬ã³ãµãªãã«é žã
ããããªã³é žãã°ã«ã³ã³é žããªã³ãŽé žãããã³
é žããã³ãã«é žãæ¡ç®é žãã·ãã©ã³ã³é žãã¹ãã¢
ãªã³é žããã«ããã³é žãã€ã¿ã³ã³é žãã°ãªã³ãŒã«
é žããã³ãŒã¹ã«ãã³é žãããã³ã¹ã«ãã¢ãã³é žç
ãé žä»å 塩圢æçšé žãšããŠæ¡çšããåŸããææ©ã
ãã³ç¡æ©é žãé©æãããã®ã§ããã ã«ããªã³äº€ææš¹èã§ã®å¡©ãçšãããããããã
ã¯çµå£çãªæç¶æŸåºç調補ãå¯èœã«ããããªããª
ãéé¢ã®å¡©åºãŸãã¯çç©åŠçãªåžåå€éšæããã
ãã®æš¹èå¡©ãããã€ãããšé·æéã«ããã€ãŠè§£é¢
ãããããã§ããããããã€ãŠããããæš¹èå¡©ã
åæ§ã«æ¬çºæã«ãããæå¹ãªååãšããŠæ¡çšãã
åŸãç¯å²å ã«ããã®ã§ããããã®ã»ãå¥ã®è¬å€ç
ã«å容ãããå¡©ããææãªãã°æ¡çšããããæ°å€
ãã®ãã®ãããªå¡©ã容æã«èããããåœæ¥è ã«ã
ã€ãŠã¯ãæãããªããšã§ããã äžè¬ã«æ¬çºæã®æŽ»æ§äœã¯ãéåžžã®æ¹æ³ã§éé¢ã®
å¡©åºãªãããã®é žä»å å¡©ã®åœ¢ã§èª¿è£œåé¢ãåŸãã
ã®ã§ãããå žåçãªå¥œãŸããé žä»å å¡©ã®äŸç€ºã¯ã
ã§ã«ç€ºãããšããã§ãããæ¬çºæã®æŽ»æ§äœãåºåœ¢
ãªããçµæ¶äœã®é žä»å å¡©ã®åœ¢ã§åé¢ãçšããã®ã
奜ãŸããããäœçãã®çç±ã§æŽ»æ§äœãéé¢ã®å¡©åº
ã®æ¹ã§çšããå¿ èŠããããšãã¯ãéåžžã®æ¹æ³ã«åŸ
ããåŸãããšãã§ããã§ããããäŸãã°èª¿è£œã®ã
ãã®åå¿ã溶åªäžã§è¡ãªããã€ãã§æº¶åªãèžçºã
ãããŠã»ãšãã©ç¡è²æ²¹ç¶ãšããŠåå¿çæç©ããã
ãšããåé¢ãããå¡©é žå¡©ãšãå¥ã®å¡©ãæ°Žäžã«æº¶è§£
ããã¢ã³ã¢ãã¢ãæ°Žé žåã¢ã³ã¢ããŠã ãçé žãã
ãªãŠã ãªããä»ã®é©åœãªå¡©åºæ§ç©è³ªã®ããšãå¡©åº
ã§äžåãã解é¢ãããå¡©åºãé©åœãªãšãŒãã«ãã
ã³ãŒã³ãªã©ã®æº¶åªã§æœåºããæœåºæ¶²ã也ç¥ããã€
ãã§ç空äžã§ä¹Ÿç¥ãããããåå¥èžçããããšã«
ãã€ãŠã§ãããä»å å¡©ã¯ãŸãéåžžã®æ¹æ³ã«ããé
é¢å¡©åºãã調補ãããé©åœãªæº¶åªäžã«éé¢å¡©åºã
ã²ãããã溶解ãããç¹å®ã®ææã®é žã§é žæ§å
ããå€ãã®å Žåãé žä»å å¡©ã®æ²æŸ±ã®åœ¢ãšãªããä»
ã®å Žåãææã®å¡©ã¯æº¶æ¶²ãå·åŽããããéå°ã®æº¶
åªãèžçºãããããé žä»å å¡©ã®åé¢ã®ããã®åæ§
ãªå ¬ç¥ã®æ¹æ³ã§åé¢ãããããããããå Žåã«
ã¯ããŸãé žä»å å¡©ã¯åå¿çæç©ã®äžåããã溶åª
溶液ã«ç¹å®ã®é žãæ·»å ããããšã«ãããåå¿ç©ã
ã調ç¯åé¢ããããã æäžåœ¢æ æ¬çºæã«ãã䜿çšã®ããã®åäœæäžåœ¢æ ã¯ã©ã®
ãããªé©åœãªãã®ã§ãããããåŸæ¥ã®ã¿ã€ãã®ã
ã®ã§ããããçµå£çæäžã®ããã«ã¯ãåäœæäžåœ¢
æ ã¯ãäžè¬ã«åœè©²æŽ»æ§ãªé£æ¬²æžéæ§ååç©ãçŽ
100ã300mgã奜ãŸããã¯çŽ100mgãå«æããŠãª
ããçŽè žæœçšãšããŠã®çŽè žçšåº§è¬ã®åœ¢ã§ã¯ãåäœ
æäžã¯éåžžåœè©²æŽ»æ§ãªé£æ¬²æžéæ§ååç©ãçŽ50ã
ã600mgã奜ãŸããã¯çŽ300mgãå«æããããã§ã«
è¿°ã¹ãããã«ãåœè©²é£æ¬²æžéååç©ã¯å¥œãŸããã¯
è¬å€ã«å容ããããã€ãªã€ãŒãšãšãã«ãªããçµå
ãããŠæœçšãããã åœè©²æè¡ã®éåžžã®å®æœã«ããã°ã掻æ§ãªé£æ¬²æž
éæ§ååç©ã¯äžè¬ã«æ¯æ§ã®ãªãåºäœãªãã液äœã§
ããè¬å€çãªåžéå€ãªãããã€ãªã€ãŒãšå ±çšãã
ãããããæ··åãã€ãªã€ãŒãããçš®ã®é©çšã«ãšã€
ãŠã¯å¥œãŸãããã®ã§ããããã®çµæã¯ãã¿ãã¬ã
ããç²æ«ãã«ãã»ã«ã液ç¶æº¶æ¶²ããšãã«ãžãšã³ãª
ãããµã¹ãã³ãžãšã³ãããã«çµå£çæäžã«ç¹ã«æ
å©ãªå¥ã®æçšåœ¢æ ããšãããšãã§ããã液äœãªã
ãå液äœã®åžéå€ãçµå£ç䜿çšã«ã¯æ¡çšãããã
ãã®ãããªåªäœã¯ã次ã®ããšã溶åªãšãªãåŸãã
å«ã¿ããã液äœåžéå€ã®åºæ¬çãªå¶éãšãªãããš
ã¯é©åæ§ãšå¿«é©æ§ãšã§ãããçµæã¯ããšã¢ãã»ã
ã³ãªãããã®é žä»å å¡©ãç±³ãã³ãã³ãã³ãŒã³ã¹ã¿
ãŒãããããã¹ã¿ãŒããã©ã¯ããŒã¹ããµãã«ããŒ
ã¹ããŒã©ãã³ãã¿ã«ã¯ãã¹ãã¢ãªã³é žãã¹ãã¢ãª
ã³é žãã°ãã·ãŠã ãã«ã«ããã·ã¡ãã«ã»ã«ããŒ
ã¹ãã¬ã ãäŸãã°ã¬ã ã¢ã«ã·ã¢ããã©ã¬ã³ãã¬
ã ããã¯ã«ããããŠãçã®ãããªåºåœ¢åžéå€ãã
ã³ïŒãŸãã¯ã¿ãã¬ããå©å€ãšæ··åãã圢ããšãã
è¬å€çæäœã§çšããããã¿ãã¬ããåç©è³ªã¯ãã
ããã掻æ§æåãšã®äžé©åæ§ããªããã°çšãåŸ
ãã掻æ§æåã¯ã¿ãã¬ããåããããããã®ã»ã
ä»ã®å ±æŽ»æ§ç©è³ªããªãããããªãã§ãã³ã³ããŠã³
ãåããåŸããå¥æ³ãšããŠã掻æ§æåã¯æŽ»æ§ãªã¢
ãžãŠãã³ããšå ±ã«ãªãããããªãã§ãŒã©ãã³ã«ã
ã»ã«ã®ãããªåžåå¯èœãªç©è³ªã®ã«ãã»ã«ãšãªã€ãŠ
çšãããããã®åœ¢ã§æœçšããããã掻æ§æåãé«
æ¿åºŠã«ããŠãã¿ãã¬ããåããç²è¬ã®äœ¿çšã«ãã
æ¡çšãåŸããä»ã®æ æ§ã§ããç²æ«ã®æŽ»æ§æåã¯ã¢
ãžãŠãã³ããšå ±ã«ç²æ«ã®å°å ãšãªã€ãŠçšããã
ãããã®ã»ãã«ã掻æ§æåã¯ã以äžã®ãããªæ æ§
ãšãªã€ãŠãçµæç©ãšãªããçµæç©ã¯çš®ã ã®é£ç©ãš
æ··åããåŸããé·æã®æŽ»æ§ç¶æã«ã©ãããŒãåãª
ããè žçšã«è¢«èŠãããã¿ãã¬ããã®åœ¢ã§èª¿è£œãã
ããå¶é žæãªããé®çå€ãäŸãã°æ°Žé žåã¢ã«ãã
ãŠã ã²ã«ãçé žã«ã«ã·ãŠã ãé žåãã°ãã·ãŠã ãª
ããããªã±ã€é žãã°ãã·ãŠã ãã¢ã»ãã«ãµãªãã«
é žãããšãã»ãã³ãããããã·ããšã³çãšæ··åã
ãããããšããã«ãã¿ã«ãŸãã¯ä»ã®ãã«ããã«é ž
ç³»é®çå€ãŸãã¯éº»é å€ãäŸãã°ã³ãã€ã³ãšããšæ··
åããããèè žéšäœäžã§å±æç麻é å¹æå€ãäŸã
ã°ããã«ã€ã³å¡©é žå¡©ãããã«ã€ã³çãšæ··åãã
ããå©å°¿å€ååç©ãäŸãã°ã¯ãããã¢ãžãããã
ãã¯ãããã¢ãžãçãšæ··åãããããŸãã¯ä»ã®ã¢
ãžãŠãã³ããšãå¢éå€ãäŸãã°ã¡ãã«ã»ã«ããŒã¹
ãšãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãªããäžè¿°ã®ç©
質ãšã®å ±çšçã§çšãåŸãã§ãããã掻æ§æåãäž
ã€ãªãããã以äžã®ä»ã®è¬å€çã«æŽ»æ§ãªç©è³ªãšæ··
ãããããšãã¯ããã¡ãããã®ç©è³ªãé©åæ§ãæ
ããã°ãªããæ¬çºæã®æŽ»æ§æåã®è¬å¹ãæžå°ãã
ããããŠã¯ãªããªããäžè¿°ãã圢ã®ã»ããæ¬çºæ
ã®çµæç©ã¯ãŸããã€ã³ãã€ããœããããªã³ã¯ãã¬
ã ãç³è¬ãã·ãããããšãªãã·ã«çã®åœ¢ããšãåŸ
ããã©ãããŒãçšã®ã¿ãã¬ããã³ãŒãã€ã³ã°ãšã
è žçšã³ãŒãã€ã³ã°ã®ããã®æç®ãšããŠç±³åœç¹èš±ç¬¬
1907203å·ãå第2196768å·ããã³å第2433244å·
ããããä»ã®é€ççšæŸåºã¿ã€ãã®èª¿åãšããŠãæ¡
çšãåŸããã®ã¯ç±³åœç¹èš±ç¬¬2875130å·ã§ããã
çš®ã ã®è¬å€ç調åãæäœãšããŠæ¡çšããããã®ã«
ãPharmacy for various phar maceutical
formulations and procedureããããã³ç±³åœç¹èš±
第2753288å·ããã³å第2881113å·ã®æ现æžããã³
ä»å çãªè¬å€ç圢ããã€ãªã€ãŒã調åãçµæã®ã¿
ã€ãçšãšããŠæ¬çºæã®æŽ»æ§æåã¯ãåé¡ã®ç¹èš±ã®
掻æ§æåã«çœ®æããããã®ã§ããã座è¬ãšãçŽè ž
æœçšã®ããã®çµæç©ãé©åœãªåŸæ¥ã®ã¿ã€ãã®ãã®
ã§ãããäŸãã°æŽ»æ§æåãè»èãã¯ãã¯ã¹ãããª
ãšãã¬ã³ã°ãªã³ãŒã«ããŒã¹ã奜ãŸããã¯äœæž©ä»è¿
ã§è§£ãåŸããã®ãªããå»åŠãè¬åŠåéã®åœæ¥è é
ã«ãããŠçšãåŸããã®ã«åæ£ãããããã®ã§ã
ãã æ¬çºæã®çµæã«ããã掻æ§æåã®å²åã¯å€ãã
åŸããã®ã§ãããå¿ èŠãªããšã¯æŽ»æ§æåãæå¹é
ååšããããšã§ãããããªãã¡å¥œãŸããæäžéã
ãã®æäžåœ¢æ ãšãšãã«åŸãããããšã§ãããæã
ãã«ããã€ãã®åäœæäžéã®åœ¢ã¯ãã»ãŒåæã«æœ
çšããããããŒã»ã³ããŒãžã§ç€ºãã°ãæ¬çºæã«ã
ã€ãŠæ¡çšããã奜ãŸããè¬å€ççµæã§ã®æŽ»æ§æå
ã¯ãéåžžçŽ0.1ãçŽ80ééïŒ ã奜ãŸããã¯çŽ0.5ã
çŽ60ééïŒ ã§ãããå¶é žå€ãšãä»ã®å ±æŽ»æ§ç©è³ªãš
æ··ãããããªæ¶²ç¶ãšãå¢éçã¿ãã¬ããã®å Žåã®
ããããŠäœãå Žåãšããåã«æŽ»æ§ãªé£æ¬²æžéçšãš
ãä»ã®åºåœ¢æçšåœ¢ã®ããšãã¿ãã¬ããã§ã®ããã
ãŠé«ãå Žåãšãçµæç©ã®åœ¢ã«ããå€ãããã®ã§ã
ããå€ãã®åºåœ¢æäžåœ¢æ ã¯ããŒã»ã³ããŒãžãçµæ
ç©ã®ééåœãçŽ10ã60ïŒ ã§ãããåäœæçšåœ¢æ ã®
調補ã®éãåœæ¥è ã§ããã°æ°å€ãã®åäœæäžåœ¢æ
ãèãåŸããããã®æ¬èª¬æãèªãã§ãåœæ¥è ã§ã
ãã°æçœã«åœè©²æè¡ã¯ç€ºããããã§ãããã æäžæ¥é ãã§ã«è¿°ã¹ãããã«ãæ¬çºææ¹æ³ã«ããã掻æ§
ãªé£æ¬²æžéæ§ååç©ã¯éåžžçµå£çã«ã¯æäžæ¥éçŽ
100ã1000mgã奜ãŸããã¯çŽ400ã600mgã®æœçšã§
ããããŸãçŽè žæœçšã§ã¯éåžžæäžæ¥éçŽ50ã600
mgã§ããã奜ãŸããæäžéã¯ãåã 人ããã®äœ
éããã®èæ§ãæé床ã«ãã倧ããå€ããããã
ãŠã±ãŒã¹ããšã«å»è ã«ãã確å®ãããã°ãªããª
ããåè¿°ãããéã¯èšåºçµéšã«åŸããã®ã§ããã
ã«ããææã®ç¡é£æ¬²èªçºããã³äœéã³ã³ãããŒã«
ããã³ïŒãŸãã¯æžéå¹æãé·æã®æ²»çã«ãã€ãŠé
æããããã®é·ææ²»çã¯é£æ¬²æ¬ ä¹èæ§ã®çºçãæ²»
çåäœã®åŽã«ã¯èµ·ããããšãªãããã®é·ææ²»çã
å°ãªããšãïŒé±éããã«ã¯ïŒé±éã«ãããã€ãŠç¶
ç¶ããããããšãã§ããããšããããã«å ±åãã
ãèšåºè©Šéšã®èŠ³å¯ããæããã«ãªãã®ã§ããã èšåºè©Šéšã®åœ¢ã§ã®ä»¥äžã®æ²»çããã³äŸã¯ãäŸç€º
ãšã«ã®ã¿ç€ºããããã®ã§ãéå®çã«èŠããããã®
ã§ã¯ãªãã ããšã¢ãã»ãã³ã¿ãã¬ããã®èª¿è£œ 代衚çãªåäœåŸåæäžåœ¢æ ã¯ã以äžã®çµæã§ã
ãã MG ïŒ ããšã¢ãã»ãã³é žä»å å¡©ã奜ãŸããã¯å¡©é žå¡©
100.0 ïŒ ã©ã¯ããŒã¹ 126.0 ïŒ ã»ã«ããŒã¹ ïŒãã€ã¯ãã¯ãªã¹ã¿ãªã³ïŒ 54.0 ïŒ ããªãããã ïŒTMâãããã³USPXXïŒ 10.0 ïŒ ã°ãªã»ãªã³ïŒ85ïŒ ïŒ 4.9 ïŒ ã¹ãã¢ãªã³é žãã°ãã·ãŠã 3.2 ïŒ ã¿ã«ã¯ 34.1 ïŒ ãµãã«ãªã³ 78.1 ïŒ äºé žåãã¿ã³ïŒCI77891ïŒ 0.9 10 ãŒã©ãã³ 0.1 11 ã°ãªã³ãŒã¹ïŒæ¶²ç¶ïŒ 0.6 12 ã¢ã«ã·ã¢ã¬ã 4.0 13 ãŠãŒãã©ã®ãã ïŒTMâããªã¢ã¯ãªã¬ãŒãæš¹èïŒ 3.8 代衚çãªã¿ãã¬ããã®èª¿è£œæ¹æ³ã¯ã以äžã®åŠã
ãšãªããã äžèšïŒãïŒãå®å šã«æ··åããäžèšïŒããã³ïŒã®
ã¢ã«ã³ãŒã«æ§æ°Žã®æ°Žæº¶æ¶²ã§åŸ®çŽ°åãããåŸããã
也ç¥ç²æ«ã¯ãäžèšïŒããã³ïŒãšæ··åããããåã
320mgã®ã¿ãã¬ããã®åœ¢ã«å å§ããããšãã¿ãã¬
ããã¯äžèšïŒã12ãšãšãã«ç³è¡£åŠçããããããŠ
ææãªãã°äžèš13ãšã®è žçšã®ã³ãŒãã€ã³ã°ããã
ãããã®çµæã®ã¿ãã¬ããã¯èšåºãã¹ãã«äŸãã
以äžã®ããšãçµæãäžããŠããã ä»ã«ãé瀺ããããã«ããšã¢ãã»ãã³ãŸãã¯ã
ã®è¬å€çã«å容ãåŸãå¡©ãæå¹ãªç¡é£æ¬²èªçºæ§é
å«æããåäœæäžåœ¢æ ã¯å€æ°èª¿è£œãããããè¬å€
çãŸãå»åŠçæè¡ã®ç¢ºç«ãããæ¹æ³ã«åŸãåæ§ã®
æ§èœã瀺ãã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒãã®ç 究ã¯21ã®äžè¬çéæ¥å»ã«ããã
ã«ãã»ã³ã¿ãŒã»ããã«ã»ãã©ã€ã³ãã»ã°ã«ãŒ
ãã»æ¯èŒèŒç 究ã®åœ¢ã§ããšã¢ãã»ãã³ïŒãã®èš
åºè©Šéšã§ã¯å¡©é žå¡©ã®åœ¢ã§çšããããïŒããã³åœ
è¬ïŒPlaceboïŒãçšããŠè¡ã€ãã å ¬ç¥ã®ãããããã»ã¹ã±ãŒã«ïŒNatvig
scaleïŒïŒãªã¹ãã1956ïŒã«ãã20ã60ïŒ éå°äœ
éã®è¥æºæ£è ã16é±éã®æ²»çæéã®éïŒé±éã
ãšã«äœé枬å®ãããã åéæ¥å»ã¯ïŒäººã®æ£è æ²»ççšã«ã¿ãã¬ããïŒ
ç®±ãåãåã€ããïŒç®±ã¯åœè¬ã®ãã®ã§ãããæ®
ãã®ïŒç®±ãããšã¢ãã»ãã³ã¿ãã¬ãããå«ãã
ãã®ã§ããïŒã¿ãã¬ããã¯äžè¿°ã®èª¿è£œæ³ã§åŸã
ãããã®ã§ãããããšã¢ãã»ãã³å¡©é žå¡©100mg
ãå«æãããã®ã§ãããïŒ æäžéïŒããšã¢ãã»ãã³ã®æäžæ¥éã¯ã第ïŒé±ã¯
100ïŒ200mgããã®åŸã®æ²»çæé200ïŒ200mgã§ã
ã€ãã é£é€æéïŒå ±éã®é£åçš®ã®ã«ããªãŒäŸ¡ã®è¡šã¯åæ£
è ã«é åžãããããåèšãšãã«ã®ãŒæåã®æ倧
å€ã«é¢ããé£é€å¶éã¯èŠæ±ããªãã€ãã çµæïŒ ïŒ æ£è è³æ 21ã®äžè¬éæ¥å»ã¯ãè©Šéšãéè¡ããåã å¹³å
ããŠïŒãïŒäººã®æ£è ãæ²»çããã 74人ã®æ£è ã®ãã¡44人ã16é±ã®æ²»çæéãé
ããããåœè¬35人ã®ãã¡24人ãããšã¢ãã»ãã³
39人ã®ãã¡20人ã ããšã¢ãã»ãã³ã§ã®æ²»çã§ïŒäººã®æ£è ã®ã¿ã
å¯äœçšã«ããè©Šéšããå€ãããã ïŒ äœéæžé 16é±éã®æ²»çåŸã®äºã€ã®ã°ã«ãŒãã®æ£è ã«ã
ã€ãŠç€ºãããäœéæžéã®çµæã¯ãå¹³åã®äœéæž
ãç¡è¬å¹ããšã¢ãã»ãã³ã§ã®16é±éæ²»çåŸãã
ãã2.2Kgãš6.0Kgã§ãã€ããã¹ããŠãŒãã³ãã®
ïœâãã¹ããçšããããšã«ããããã®äºã€ã®ã°
ã«ãŒãã®å·®ã¯ãŒããšã¯çžç°ããŠããïŒïŒ°âå€ïŒ
0.02ïŒã ïŒã€ã®æ£è ã°ã«ãŒãããåŸãããäœéæžéã®
æéççµéããããããããïŒäœéå€åãšæé
ãšã§ïŒãã°ã©ãããäœéã®ããã«æžéããããš
ããã®ããšã¢ãã»ãã³æ²»çã16é±é以äžç¶ããŠ
ãããšãæåŸ ãããããšã瀺ãããã 16é±éåœè¬ãšããšã¢ãã»ãã³ãšã§æ²»çããŠåŸ
ãããäœéæžéã®çšåºŠã«ãã€ãŠæ£è ã®ååžãã
ãããããïŒäœéå€å察æ£è æ°ïŒãäœéå€åã®
å¹ ã¯ãåœè¬æ²»çãšæ¯ã¹ããšã¢ãã»ãã³æ²»çã«ã
ãå Žåã®æ³ãããªãçããã®ã§ãã€ãã çµè«ïŒããšã¢ãã»ãã³ã®éåžžã®æ¹æ³ã§è¥æºæ£è ãž
ã®16é±éã®æäžæ¥é400mgã®æœçšã¯é¡èãªäœé
æžéãããããããªãã¡åœè¬ã®æ£è ã§å¹³åäœé
æžé2.2Kgã§ããã®ã«å¯Ÿããå¹³åäœéæžé6.0Kg
ã§ããã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒãã®èšåºè©Šéšã§ã¯ãããšã¢ãã»ãã³ã¯
13人ã®è¥æºå©Šäººã«ãããŠãã®äœéæžéå¹æãç
究ããããããšã¢ãã»ãã³ã¯ïŒé±ãã16é±éãŸ
ã§æäžæ¥é300mgã§æœçšãããã13人ã®ãã¡ïŒ
人ã®å©Šäººã¯æ²»çã«ããäœéãæžå°ãããã®æžå°
éã¯0.2ãã8.5Kgã§å¹³åæžé2.8Kgã§ãã€ãã ïŒâHTæžéã®çšåºŠãšäœéæžéãšã®éã®çžé¢
é¢ä¿ã¯åŸãããªãã€ãã æ£è ãšæ¹æ³ïŒããšã¢ãã»ãã³ã¯ãå ¬éç 究ã«ãã
ãŠã®æäžæ¥é300mgïŒæ100mgãååŸ200mgïŒã
è¥æºãã婊人ã«æœçšãããã 圌女ãã¯æåã®ïŒã±æã¯ïŒé±éããšã«äœéã
枬å®ãããããããåŸã¯ïŒé±éããšã«è¡ãªãã
ãã枬å®ããšã«è¡æ¶²ãµã³ãã«ããšãããã©ãºã
äžã®ããšã¢ãã»ãã³ããã³å šè¡æ¶²äžã®ïŒâHT
ã枬å®ããããè¡æ¶²ãµã³ãã«ã¯æã«åæ¥ã®æäž
ãã14ã16æéåŸã«æ¡åããããããšã¢ãã»ã
ã³ã®æ¿åºŠã¯ãã¬ã¹ã¯ãããã°ã©ãã€ã«ãã枬å®
ããããBeckgaardããã³LundãJ.
Chromatgrã133ã147ã152ïŒ1977ïŒïŒ
BeckgaardããAnal.Chim.ActaïŒ99ïŒ189â
192ïŒ1987ïŒããïŒâHT枬å®ã¯Squircsã®æ¹æ³
ïŒGournal of Neu rochemistry 1975ã24ã
47ïŒã®å€æŽãçšããŠè¡ãªãããã èèªéå€çã®æ²»çãåžæããããå åæ³æµ®äž
ã®ãŸãã¯ä»ã®éãç æ°ãæããªã婊人ã¯ãã€ã
ãããè©Šéšãåããããšãèš±ãããã49ãã69
æã®ã°ã«ãŒãã®13人ã®å©Šäººã16é±éã®ã¿ã§æ²»ç
ãã¹ã¿ãŒãããèèªéå€çãšã¯å¥ã«ïŒäººãé€ã
ãŠå šãŠã®æ£è ã¯äžŠè¡ãã身äœçãªç æ°ãæããª
ãã€ããïŒäººã¯çæ£ç³å°¿ç ã§ãããããïŒäººã¯
å ããªéææ§ã§ãã€ãã å šãŠã®äººãäœå¹Žã®éè¥æºãããŸãŸã§ããã以
åå»åŠçæ瀺ã®äžã«é£äºçæ³ãè©Šã¿ããæåã
ãªãã€ãã®ã§ããã ãããã®æ£è ã®äœéã®å¹³åã¯ç 究ã®éå§æ
83.2Kgã§ã€ããèèªæ§ã®çšåºŠã¯ãçæ³äœé
ïŒNatvigã1956ïŒãè¶ããããŒã»ã³ãã§ç€ºãã
ãããã®ããŒã»ã³ãã¯16ãã111ãŸã§çµããã
ã®ã§å¹³å41ã§ãã€ãã婊人ãã¡ã¯æ²»çæéäžå¶
éãããé£äºãããããã«ã¯ããããŠããªãã çµæïŒ13人ã®ãã¡ïŒäººã®å©Šäººã0.2ãã8.5ïŒå¹³å
2.8KgïŒã®äœéæžãšãªã€ããïŒäººã®æ£è ã®äœé
ã¯å€ãããïŒäººã¯0.4ã2.0Kgå¢å ãããïŒé±é
以äžæ²»çãããæ£è ã«ãšã€ãŠæ²»çæéã®äœéå€
åã«ã€ããŠã¯ãå°ããšãïŒäººã®æ£è ã«ãããŠã
äœéæžã¯10ãã16é±ãŸã§ã®éç¶ç¶ããã å šè¡æ¶²äžã®ïŒâHTæ¿åºŠã¯ãïŒé±éæ²»çã®çµ
ãã«ã¯0.14ãã0.05ÎŒïœ/mlã®å¹³åå€ã«ãŸã§æž
å°ããã16é±éã®æ²»çã®ã®ã¡ãïŒâHTæ¿åºŠã¯
ãŸã 0.05ÎŒïœ/mlã§ãã€ããïŒâHTæžå°ã®çšåºŠ
ãšäœéæžå°ãšã®éã®çžé¢é¢ä¿ã¯åŸãããªãã€
ããè¥æºåºŠã®çšåºŠãšäœéæžå°ãšã®çžé¢é¢ä¿ãåŸ
ãããªãã€ãã å¯äœçšïŒå¯äœçšã¯ïŒäººã®æ£è ã«èªãããããïŒäºº
ã¯å£å 也ç¥ãšãªã€ãããã®ã±ãŒã¹ã¯ãã¹ãŠãã
ããã§äžæçã®ãã®ã§æ²»çãç¶ããããšã§æ¶ã
ããïŒäººã¯ãïŒé±éã®æ²»çåŸåœå䟿ç§ãšãªãã
æ¶åäžè¯çããã«æ²»çãäžæ¢ãããïŒäººã®æ£è
ã«ã¯é£æ¬²æ¬ ä¹çå¹æãåœåèªããããã ããããã¢ãŠãïŒïŒäººã®å©Šäººã¯ããšã¢ãã»ãã³ãš
ã¯é¢ä¿ãªãçç±ã§æ²»çãäžæ¢ããããããã®ã
ã¡ïŒäººã¯å€èŠ³ã¯å€ãããïŒäººã¯ïŒé±éåŸãªãã
äœéãæžããªãã®ã§æ²»çäžæ¢ãåžæãããïŒäºº
ã¯åé¡ãå€ãæ²»çã¯å®éçãªçç±ã§å»åž«ã«ãã
äžæ¢ããããæåŸã®æ£è ã¯æ²»çãããŠããªãé
ææ§ã®å»åŠçæ²»çã®ããã«ããšã¢ãã»ãã³æ²»ç
ããå€ãããã ããšã¢ãã»ãã³ïŒäžè¬ã«å®å®ç¶æ è¡ãããã®ããš
ã¢ãã»ãã³æ¿åºŠã¯ãåæéçïŒïŒnïœ/mlïŒä»¥
äžã§ãã€ããïŒäººã®å©Šäººã ãã枬å®ãããæ°å€
ã§ãããå®å®ç¶æ ã®æé«ã®æ¿åºŠã30nïœ/mlã§
ãã€ãã èšè«ïŒãã®ç 究ã¯ãããšã¢ãã»ãã³ãæã«ãããª
ãè¥æºæ§ã®å©Šäººã®äœéãæžå°ãããã®ã«æå¹ã§
ããããšãæããã«ãããäœéæžå°ã¯ãè¬ãäž
ããããŠããéãç¶æããå¯äœçšã¯ãã ããã§
äžæçã§ãã€ãã èšåºè©Šéš ïŒ äžèšãšåæ§ã«ããŠãïŒäººã®è¥æºå¥³æ§ãããšã¢ã
ã»ãã³ãæ¥é600mgã§æ²»çããïŒé±éåŸå¹³åïŒKg
ã®äœéæžãïŒé±éã§4.5KgãïŒé±éã§7.5Kgã10é±
éã§11Kgã13é±éã§13Kgã20é±éã§14Kgã28é±é
ã§16Kgã36é±éã§19Kgã44é±éã§22.8Kgæžãšãªã€
ããïŒïŒäººã®æ£è ã¯18KgæžããïŒäººã¯27.6Kgãå¹³
åã§ã¯22.8Kgã§ãã€ããïŒ èšåºè©Šéš ïŒ æ ¢æ§çè¥æºæ£è ã«ãããé£æ¬²ããã³äœéã³ã³ã
ããŒã« ãã¶ã€ã³ïŒè©Šéšã¯äºã€ã®å»é¢ã§ããšã¢ãã»ãã³ãš
åœè¬ãšã®ããã«ãã©ã€ã³ãã»ã°ã«ãŒãæ¯èŒç 究
ãšããŠèšç»ãããã è¥æºæ£è ã®äœéã¯æ£è ãæ²»çãã¹ã¿ãŒããã
åã«æž¬å®ãããæ²»çïŒé±éåŸããã®åŸã¯ïŒé±é
ããšã«17é±éã®æ²»çæé枬å®ãããã é£æã®éãšçµæã¯æ²»çéå§åã«ãããæ£è ã«
ãããŸãé£é€å©å€ã«ããè©äŸ¡ããããç 究æé
ã«ãïŒåºŠè©äŸ¡ãããã èªç±ãªé£é€èš±å¯ïŒæ£è ã¯ããããé£æã«ã€ããŠå¶
éãããããéžæããããèªç±ãªé£é€èš±å¯ãäž
ããããã é£äºäžã®å¶éããªããè¡ãªããªãç®çã¯ãã
ãšã¢ãã»ãã³æ²»çã®éé£äºæåèŠçŽ ã®èªç¶ãªå€
æŽãè¡ãªãããŠäœéæžéãã§ããããã«ããã
ãã§ããã å 容åºæºïŒãããã€ããã»ã¹ã±ãŒã«ã®çæ³äœéã«
察ãã20ã95ïŒ ééã§ããã20ãã70æã®å¹Žä»£
ã®æ£è ãè©Šéšãåããã æ£è ã¯äºã€ã®éšéã§ã®å€æ¥æ£è å»é¢ã«å®åžžç
ã«å¯Ÿå¿ããããããããŸãã¯é£æ¬²æ¬ ä¹è¬ãé£é€
æéãªããé£é€å¶éãªã©ãçšããŠäœéæžéã以
åè©Šã¿ãŠããŠå»é¢ã«ãã§ã«æ £ããŠãããã®ã§ã
ã€ãã æäžéïŒïŒé±éã¯æ¥éïŒã¿ãã¬ãããïŒåãåœè¬
ãšããšã¢ãã»ãã³ã®ã¿ãã¬ãã100mgã®æäžé
ã§ããã®åŸæ²»çæéäžïŒã¿ãã¬ãããïŒåã®æ¥
éã§ãã€ããä»ã®å»çåŠçã¯ç 究ã®éãªãããª
ãã€ãã é£æã®éãšè³ªïŒïŒé±éæ¯æ¥æ¶è²»ãããå šãŠã®é£æ
åçš®ã®å³å¯ãªèšé²ãåé ç®ããšã«åã«è¡ãªã
ããïŒã±æå»çæéã¯ïŒåè¡ãªããããæ¯æ¥ã®
é£äºèšé²ã¯ããã«åæãããïŒäººã®å°éã®é£é€
çæ³æè¡åž«ã«ããåé¡ããã³ã³ããŠãŒã¿ããã°
ã©ã ãïŒCAMPâã·ã¹ãã ã»ãã³ããŒã¯ç é¢å
äŒDanish Hospital InstituteïŒãã«å ¥ããã
ããããã¯ãšãã«ã®ãŒãããã±ã質çæ°Žåç©ã
ãã³èèªå«éãçŸåšã®ãã³ããŒã¯ã®ã¡ããŠãŒã®
600ã®ããããã®é£ææ¯ã«ã€ããŠæ å ±åããã
ã®ãå«ãã§ããã çµæïŒ ïŒ æ£è è³æ 111ã®æ£è ã®ãã¡73人ã17é±éã®æ²»çãå®äº
ããã ïŒäººã®æ£è ã¯å¯äœçšã«ããè©Šéšããå€ããã
ãã19人ã¯å€èŠ³äžå€ãªããå¹ææ¬ ä¹ã®ããäžæ¢
ããããããã®æ£è ã¯ãè©Šéšèšç»ã§åã«è¿°ã¹ã
ããæé€åºæºã«ããä»ã®æ£è ãšãšãã«åæãã
ã®ããå€ãããã æ§å¥ã幎霢ãäœééé床ã蚺çæã«ããæ£è
ã®ååžã¯äžèŠ§è¡šã«ãŸãšãããããååžã¯äºã€ã®
ã°ã«ãŒãã«æ¯èŒãããã åæã«äŸããã73人ã®æ£è ã®47人ã¯ãè©Šéšã«
å ¥ã€ããšãã¯ãããŠäºã€ã®èšºçæã«ãŸãããã
ãã®ã§ãããæ®ãã®26人ã¯å šãŠãã§ã«äœéæžé
ã®è©Šã¿ã蚺çæã§åããŠãããæ¬è©Šéšã®åïŒã±
æã®éã«â12KgããïŒïŒKgã®ç¯å²ã§äœéå€åã
ãã€ããã®ã§ãã€ãã ïŒ äœéå€å 17é±éã®ããšã¢ãã»ãã³ã§ã®æ²»çã®ã®ã¡ãã
äœéã«å€åããªãã€ããäœéå€åã®ã®å¹³åå€ã¯
0.06Kgããã®ç¯å²ã¯â9.4ããïŒ7.8Kgã§ããã
åœè¬ã§ã®æ¯èŒçµæã§ã¯ãå¹³å1.6Kgã®äœéå¢ã§
ãã€ãããã®äºã€ã®èšºçæããåŸãããçµæã§
ã¯å®è³ªçãªå·®ã¯ãªãã€ãã äºã€ã®æ²»çã°ã«ãŒãã«ãã€ãŠããããäœéå€
åã®æéçµéãå³ç€ºããããæ²»çã®åæã§ããŸ
ãã¯æ²»çã®æéäžã®ã©ã®æç¹ã§ãäœéæžå°ã¯ç®
ç«ã€ãŠããªãã æ²»ç17é±éåŸã«åŸãããäœéå€åã®çšåºŠã§ã®
æ£è ã®ååžãå³ç€ºããããŠããšã¢ãã»ãã³æ²»ç
æ£è ã«å¯ŸããããããŠå¹³ååããååžãšã»ãšã
ã©äœéå¢å ã®ãªãããšã瀺ãããã 11人ã®æ£è ãããšã¢ãã»ãã³æœçšäžã«äœé
3.0Kg以äžã®æžéã§ãããïŒäººã®ã¿ãåœè¬ã§ã
ã®ãããªäœéæžãããããããã®11人ã®ããšã¢
ãã»ãã³æ£è ã®æ€æ»ã§å¹Žéœ¢ãäœééé床ã®ç¹å¥
ã®ååžã瀺ããããšããããšããªãã€ãã ïŒ ãšãã«ã®ãŒæåããã³ããã±ã質ãèèªãã
ã³çæ°Žåç©æåç 究æéäžãé£ææåã®å€åã¯
ã¿ãããŠããªããåèšãšãã«ã®ãŒæåãããã°
ã質ãèèªããã³çæ°Žåç©ã§ïŒé±éã§æ¶è²»ãã
ãéã¯ããããŠä»¥åããŸãæ²»çæéäžãã»ãŒå
ãã§ãã€ãã çµè«ïŒãã®ç 究ã®åã«ãïŒåã®ïŒã®æ£è ã¯é£é€å¶
éãæã«ã¯è¬å€ãçšããæ²»çã䜵çšããŠäœéæž
éã®è©Šã¿ãããŠèšºçæã«ã¯æ £ããŠãããããã
ã€ãŠãèªç±ãªé£é€èš±å¯ã§ã®ãã®åŸã®è¬å€è©Šéšã§
ã¯ãã®ãããªæ£è ã«ãšã€ãŠäœéæžå°ããããã
ã®ã¯å°é£ã§ãã€ããããããªããããããé£æ¬²
ããã³äœéã³ã³ãããŒã«ã¯èªããããã ãã®ç 究ãã¶ã€ã³ãããã¯é£é€å¶éããªãã
è·ããŠããªããããã®ç®çã¯ããšã¢ãã»ãã³æ²»
çã®éãé£äºæåã®æåã®èªç¶ãªå€åãšã®é¢é£
ã§äœéæžå°ããã³ïŒãŸãã¯ã³ã³ãããŒã«ãæ±ã
ãããšã§ãããåèšãšãã«ã®ãŒæåã®äžå€ãªã
ãæžå°ã«ãããããã€ã³éã®å¢å ãæåŸ ããã
ã®ã§ããããšãã«ã®ãŒã®ïŒæåãŸãã¯åèšãšã
ã«ã®ãŒæåã®å€åã¯ãªããç 究äžèªããããªã
ã€ããããã®ããäœéæžéãèªããããªãã€ã
ã®ã§ããã èšåºè©Šéš ïŒ 20ïŒ ä»¥äžã®äœéééã®å€æ¥æ£è 21人ãã¹ãŠã«å¯Ÿ
ã300ã400mgã®æäžæ¥éããšã¢ãã»ãã³ãæœçšã
ãããäœéééã®å¹³åã¯41ïŒ ã§ãã€ãã16人ã®æ£
è ã¯12é±éã®æ²»çãåããïŒäººã¯ïŒãïŒé±ã®ééš
åçãªæ²»çã®ã®ã¡äžæ¢ãããããã¯ãã¹ãŠè¬å€æ²»
çç¶äžã®åå ã®ããã§ã¯ãªãã45æãŸã§ã®è¥å¹Žæ£
è ã¯45æ以äžã®ã°ã«ãŒãã«æ¯ã¹ãäºæ³ã©ãããšã
ã«ã®ãŒæåãé«ãç©çç掻æ§ãããé«ãã¬ãã«ã§
ããããšãç¹åŸŽã§ãã€ãã 20人ã®æ£è ãäœéãæžããå¹³åã®äœéæžã¯3.1
Kgã§ãã€ãããã倧ããªäœéæžå°ã¯è¥å¹Žã°ã«ãŒã
ã®æ£è ã«èªãããããå€æ¥æ£è ã®12é±éã®æ²»çã
åãã16人ã®å¹³åäœéæžéã¯ãè¥å¹Žã°ã«ãŒãã§
4.8KgïŒïœïŒïŒãs.d.ïŒ2.5ïŒãäžæ¹è幎ã°ã«ãŒãã®
ããã¯2.2KgïŒïœïŒïŒãs.d.ïŒ1.2ïŒã§ãã€ããã
ã®äºã€ã®å¹Žéœ¢ã°ã«ãŒãéã®äœéæžéã«ãããå·®ã¯
éèŠã§ããã察ã«ãªã€ãŠããªãå€ã«å¯Ÿããã¹ããŠ
ãŒãã³ãã®ïœâãã¹ãã¯ïŒ°âå€ã0.02ã§ãã€ãã
ãã®äºã€ã®å¹Žéœ¢ã°ã«ãŒãããããã«å¯Ÿããäœéæž
å°ã®æéçµéãå³ç€ºããããã€ãã®å€åãæãã
ã«ããããè©Šéšã§ã®å šãŠã®ç¹ã§ã45æããäžã®ã°
ã«ãŒãã§ã®äœéå€åã¯45æ以äžã®ã°ã«ãŒãã«ãã
ããã倧ãããäŸãã°ïŒé±éã§ã¯ã45æ以äžã®ã°
ã«ãŒãã®å¹³åäœéæžéã¯1.5Kgããšããã45æ以
äžã®ã°ã«ãŒãã§ã¯2.5Kgã§ãã€ããïŒé±ç®ããã
ãïŒKgãš3.5Kgã10é±ç®ããããïŒKgãããåäž
åã€ãã®ãšïŒKgããããŠ12é±ç®ã®çµãã§ã¯ããã
ã2.5Kgã®äœéæžãšã»ãŒïŒKgã§ãã€ãã èšåºçè©Šéšã§ã®ç æŽã¯æ£è ãžã®ã¢ããã€ã¹ãå ¥
ã€ãŠãããé£é€å¶éã¯äžå¿ èŠã§ããããšãé£é€ç¿
æ £ãå€ããå¿ èŠãªãããšã平垞ã©ããã®é£ç©ããš
ãããã«ããããŠç©ºè ¹ãšæºè ¹ã«åŸã€ãŠé£é€ã®éã
決ããããã«ãšèšãããŠãããïŒãïŒã®å¯äœçšã
å ±åãããã ãã§ãïŒäººã®æ£è ãå£å 也ç¥ã§äžæº
ã蚎ããåãæ°ã蚎ãããããããã®äžèª¿ã¯ãã¹
ãŠãã ããã§åŸŽåãããã«æ²»çãããŠãããã¡ã«
æ¶ãããïŒäººã®æ£è ãé çã®é®éã瀺ãããè¡æ¶²
åçãèèããã³è èæ©èœã®å®éšå®€ã§ã®èŠ³å¯ã§ã¯
æ²»çäžãªããç®ç«ã€ãå€åã¯ãªãã€ããECGã¢
ãã¿ãŒã¯å šæ£è ã«ã€ããŠæ²»çã®åããã®æéãã
ã®åŸæ£åžžã®ãã¿ãŒã³ã瀺ããã ãã®è©Šéšã§ãå šè¡æ¶²äžã®ïŒâHTæ¿åºŠã®æ倧æž
å°ã¯0.07ÎŒïœ/mlã®å€ããïŒé±éã®æ²»çæéåŸç€º
ãããæ²»ççµäºåŸïŒé±éã§ãïŒâHTæ¿åºŠã®å¹³å
ã¯0.14ÎŒïœ/mlãšãªããæ£åžžã®ïŒâHTã¬ãã«ã«å
埩ã瀺ãããããšã¢ãã»ãã³ã®å®å®ç¶æ æ¿åºŠã¯å š
ãŠæ¥µããŠäœãã€ãããã ïŒäººã®æ£è ã®ã¿è¡ããã
æ¿åºŠãåæé床ã®ïŒnïœ/mlãè¶ãããã®æ£è ã«
察ããå®å®ç¶æ æ¿åºŠãïŒãš20nïœ/mlã®éã§å€å
ãããããšã¢ãã»ãã³ã®ããããŠäœãå®å®ç¶æ æ¿
床ãšé¢ä¿ãªããå šè¡æ¶²äžã®ïŒâHTã¯æ²»çäžåŒ·åºŠ
ã«æžå°ããããšã¢ãã»ãã³ãããããŠäœæ¿åºŠã§ã¯
è¡å°æ¿ãžã®ïŒâHTæåã®åŠšããããããšã瀺ã
ãããCNSâåºæ¿è¬å¹æã¯èšåºè©Šéšã®éãªãã
èŠãããªãã€ãã ãã®èšåºè©Šéšã®çµæãããšã¢ãã»ãã³ã¯12é±é
ã®æ²»çæéã«ãããè¥æºããããæ£è ã§ã®é£æ¬²ã
ãã³äœéã®ã³ã³ãããŒã«ããã³æžå°ã«å©ããããš
ã瀺ãããã èšåºè©Šéš ïŒ ãã¶ã€ã³ïŒããšã¢ãã»ãã³ãšåœè¬ãšã®ããã«ã»ã
ã©ã€ã³ãã»ã°ã«ãŒãæ¯èŒç 究ã§äºãå å ¥ããŠã
ãè¥æºæ£è ã«ã€ããŠè¿œè·¡ç 究ããªããããäžèš
ã®ç 究ã®çµæã¯ãããã¯ã³ãã³ããŒã²ã³ã®äºã€
ã®å€æ¥æ£è 蚺çæã§è¡ãªããããã®ã§ãããã
äžèšèšåºè©ŠéšïŒã§ãããŸã§ã«ãã§ã«å ±åããã
ãã®ã§ããã æ¹æ³ïŒããã«ã»ãã©ã€ã³ãç 究ã§ã®17é±éã®æ²»ç
çµäºåŸããã®äºã€ã®èšºçæã®äžã€ã®æ£è å šå¡ã
ããšã¢ãã»ãã³æ²»çãåãããããŸãã¯ç¶ç¶ã
ãããéããããã ãã®ç 究ã®çŽåã®æ²»çæéã«ãããŠèªç±ãªé£
é€ã®èš±å¯ãæ¯æããã®ãšã¯å察ã«ãä»åºŠã¯æ£è
ã®é£äºã®ã¢ããã€ã¹ãåããã圌çã¯çŽ5000ã
ããžãŠãŒã«ãžã®é£é€äžã®å¶éããã³é£æ¬²æ¬ ä¹æ²»
çãçµã³ã€ããäœéæžå°ããã°ã©ã ã®å©ç¹ã«ã€
ããŠèª¬æãåãããããããã»ãã«ã¯ãã©ããª
é£é€å¶éãè¡ãªãããã決å®ããããã³ã³ãã
ãŒã«ãããããè©Šã¿ã¯ãªãããªãã€ãã ããšã¢ãã»ãã³ã®æäžæ¥éã¯600mgã§ãã€
ããæ£è ã¯ãæïŒåäœé枬å®ãšå®éšå®€çã³ã³ã
ããŒã«ã®ãã蚺çæã蚪ãããæ£è ã¯æé«ïŒã±
æéããšã¢ãã»ãã³ãæäŸãããã çµæïŒããã«ã»ãã©ã€ã³ãè©Šéšãçµãã35人æ£è
ã®ãã¡ã28人ã¯ïŒé±é以äžã«ãããããšã¢ãã»
ãã³ã§ã®æ²»çãåããã10人ã®æ£è ããã®çŽå
ãŸã§17é±éã®éããšã¢ãã»ãã³ã§ã®æ²»çãåã
ãŠãããã18人ã®æ£è ã¯ç¡è¬å¹ç©ãåããŠã
ãã åŸãããå¹³åã®äœéæžéã¯16é±ã®æ²»çæéåŸ
ã§5.2KgïŒSDïŒ5.5ãïœïŒ28ïŒã§ãã€ãã ããšã¢ãã»ãã³ã§åŸåããæ²»çãåããŠãã
æ£è ã«å¯ŸããŠã¯ãå¹³åäœéæžéã¯2.1Kgãäžæ¹
ç¡è¬å¹ç©ã§äºãæ²»çãããŠããæ£è ã®ãã®ã¯
6.9Kgã§ãã€ãã æ²»çæéäžåŸãããäœéæžéã®çšåºŠã¯è¡šã«ã
ããå³ç€ºãããäžè¿°ããçµæã確ãããããã ïŒäººã®æ£è ã«ã€ããŠã¯ã10Kg以äžã®äœéã芳
å¯ãããã圌çã¯å¹³åæé21é±éã®è©Šéšäžã«å¹³
å13.6Kgæžéããã 11人ã®æ£è ã¯ãïŒã±æéããšã¢ãã»ãã³ãå
ããããã®ç 究ã®çŽåããã«ã»ãã©ã€ã³ãç 究
ã§17é±éæ²»çæéãçµãŠããããšã«ããã圌ç
ã¯æ²»çãïŒã±æããããšã«ãªã€ããïŒã±æã®æ²»
çåŸã«10Kgã®å¹³åäœéæžãšãªããŸã§ã®äœéå€å
ã®çµæãå³ç€ºããè©Šéšã«ãããã€ã11人ã®æ£è
ã«ããããã®æ³šç®ãã¹ãäœéæžããã©ããã€ã
ã¯ã«é瀺ãããã è°è«ïŒèªç±ãªé£é€èš±å¯ã€ãã§ã®ããã«ã»ãã©ã€ã³
ãç 究ã®ããã ãããšã¢ãã»ãã³ãåœè¬ã°ã«ãŒ
ãããªããèããäœéæžå°ãèªããããªãã€
ããããšã¢ãã»ãã³ã§æ²»çãããæ£è ã¯å¹³å
0.5Kgæžããäžæ¹åœè¬ã°ã«ãŒãã¯1.1Kgã®äœéæž
ãšããé¡èæ§ãèŠããããäœéæžã®æé«ã¯åã¯
åœè¬ã§æ²»çãããæ£è ã«ãã€ãŠåŸãããã è¥æºæ£è ã«ãããŠã¯ããããšã³ãã«ãã³ãã
ãšã³ã¡ãã©ãžã³ããã³ããšã³ãã«ã©ãã³ãåã
ãŠåæ§ã«ãã¶ã€ã³ãããè©Šéšãšé¡åçæ¯èŒã«ã
ããŠãããšã³ãã«ã©ãã³ã®ã¿ã12é±é以äžæå¹
ã«äœéæžããããããŠãããïŒPinderãR.M.
ãïŒããšã³ãã«ã©ãã³ïŒãã®è¬çåŠçæ§è³ªãã
ã³è¥æºæ§ãžã®æ²»çç¶ã®å¹æãDrugs 1975ã10
ïŒïŒïŒã241ã323é ïŒãããããæ²»çã®ã¯ããã®
ïŒé±éã§ããšã³ãã«ã©ãã³ãèæ§ãçºçããã
ãããšãå ±åãããŠãããïŒStunkardãA.SïŒ
è¥æºæ§æ²»çäžã®ããšã³ãã«ã©ãã³ãLancet
1973ãïŒã503ïŒããã®ç 究ã§ã®çµæã¯ãããšã¢
ãã»ãã³ãïŒã±æã®æ²»çåŸé£æ¬²æ¬ ä¹çµæãçºç
ãããŠããããšã瀺ãããã ããã«ãããšã¢ãã»ãã³ã¯ãåç¬ãããé£é€
æ瀺ã€ãã§äžããããæ¹ãããããšãçµè«ã§ã
ãããã¡ããèªç±ãªé£äºããããããæ£è ã«ã
ããŠãæå¹ã§ã¯ããã çŽè žãžã®æœçš ããçš®ã®çç©è¬å€åŠçç 究ã«ãããŠã¯ãæ¯æ¥ïŒ
åçŽè žçã«æœçšãããããšã¢ãã»ãã³300mgãå«
ãåäœãµã€ãºã®åº§è¬ãçµå£çã«æå¹ãªæ¯æ¥ã®æäž
éã®ããšã¢ãã»ãã³600mgãçšããŠåŸãããã®ãš
åãè¡ãããæ¿åºŠãåŸãå¹æãããããšã枬å®ã
ãããããåºããããç¯å²ãæ¡çšãããããšã«ãª
ããã50mgã®ããšã¢ãã»ãã³ãšããäœãå«éã®åº§
è¬ãçšãããã600mgãæ¥æ¯ã®çŽè žçæçšããã
ããŠå¹æçã§ããããšãã«å°ãªãåäœæäžéã«å
ãããšããããããã®è©Šéšã§ãã¹ãããã座è¬ã¯
éåžžã®è解ãããã座è¬çšããŒã¹ã«ããšã¢ãã»ã
ã³ãåäžã«åæ£ãããŠå«ãŸãããã®ã§ããã äžè¿°ã®ããšãããããæ£è ãç¹ã«è¥æºãããã
æ£è ã®é·ææ²»ççšã®æ°èŠæ¹æ³ãé£æ¬²ããã³äœéã³
ã³ãããŒã«æžå°ãç®çãšãããããŠããã«ããæ¬
çºæã®ä»å çç®çã®ãã¹ãŠãéæãããã®ã§ãã
ããæ¬çºæã«ãã€ãŠäžããããã®ã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ããšã¢ãã»ãã³ããã³ãã®è¬å€çã«å容ãåŸ
ãå¡©ãããªã矀ããéžã°ããé£æ¬²æå¶çååç©ã®
é£æ¬²æå¶ã«æå¹ãªéãå«ãã§ãªãè¥æºããããæ£
è ã«ãããŠæ£è ã®åŽã«é£æ¬²æ¬ ä¹çèæ§çºçããã
ãããšã®ãªãé·æéããŒã¹ã§ã®é£æ¬²ããã³äœéã®
ã³ã³ãããŒã«ããã³æžå°çšå€çµæç©ã ïŒ é·æéããŒã¹ãå°ãªããšãïŒé±ã®æéãå«ã
ã§ãªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒ é£æ¬²æå¶çååç©ãçŽ600mgãŸã§ã®éã§è¬å€
çã«å容ãåŸããã€ãªã€ãŒãšãšãã«ååšããŠãªã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯ç¬¬ïŒé ã«èšèŒã®çµæ
ç©ã ïŒ é£æ¬²æå¶çååç©ãçŽ100ã300mgã®éååšã
ãŠãªãçµå£çåäœæäžéã®åœ¢ããšãç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé ãªãã第ïŒé ã®ããããäžã€ã«èšèŒã®çµ
æç©ã ïŒ é£æ¬²æå¶çååç©ãçŽ50ã600mgã®éååšã
ãŠãªãçŽè žç座è¬ãããªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
ãªãã第ïŒé ã®ããããäžã€ã«èšèŒã®çµæç©ã ïŒ é£æ¬²æå¶çååç©ãçŽ100ã300mgã®ããšã¢ã
ã»ãã³ã®è¬å€çã«å容ãåŸãé žä»å å¡©ã§ããã¿ã
ã¬ãããããªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãªãã第ïŒ
é ã®ããããäžã€ã«èšèŒã®çµæç©ã ïŒ åœè©²ååç©ãããšã¢ãã»ãã³å¡©é žå¡©ã§ããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/261,479 US4442113A (en) | 1981-05-07 | 1981-05-07 | Long-term weight reduction of obese patients using femoxetine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57192315A JPS57192315A (en) | 1982-11-26 |
| JPS6121602B2 true JPS6121602B2 (ja) | 1986-05-28 |
Family
ID=22993481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57075588A Granted JPS57192315A (en) | 1981-05-07 | 1982-05-07 | Obese patient long-term weight reduction employing femoxetine |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4442113A (ja) |
| JP (1) | JPS57192315A (ja) |
| DE (1) | DE3213091A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK149624C (da) * | 1983-03-07 | 1987-02-02 | Ferrosan As | Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne |
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| US4895845A (en) * | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
| US5635535A (en) * | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
| US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
| US6852342B2 (en) * | 2002-03-26 | 2005-02-08 | Avoca, Inc. | Compounds for altering food intake in humans |
| US20060084636A1 (en) * | 2004-10-18 | 2006-04-20 | Maria Alemany | Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same |
| US20060084637A1 (en) * | 2004-10-18 | 2006-04-20 | Maria Alemany | Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same |
| US20100247453A1 (en) * | 2006-07-12 | 2010-09-30 | Thomas L. Jones | Composition and method of treating a sore throat |
| US7754234B2 (en) * | 2006-07-12 | 2010-07-13 | Jones Thomas L | Composition and method of treating a sore throat |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
-
1981
- 1981-05-07 US US06/261,479 patent/US4442113A/en not_active Expired - Lifetime
-
1982
- 1982-04-07 DE DE19823213091 patent/DE3213091A1/de not_active Ceased
- 1982-05-07 JP JP57075588A patent/JPS57192315A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57192315A (en) | 1982-11-26 |
| US4442113A (en) | 1984-04-10 |
| DE3213091A1 (de) | 1982-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI314053B (en) | Use of compounds that are effective as selective opiate receptor modulators | |
| Weiser et al. | The pharmacologic approach to the treatment of obesity | |
| CN100540001C (zh) | å å«æ¢æ³»è¯ååå¡éçŽ æåå¡éçŽ è¡çç©çç»å | |
| RU2201272C2 (ru) | ÐÑОЌеМеМОе ОМгОбОÑПÑПв желÑЎПÑМП-кОÑеÑМПй Ð»ÐžÐ¿Ð°Ð·Ñ | |
| WO1995011034A1 (en) | Composition for weight reduction containing ephedrine and a mineral salt or chelate | |
| JPS6121602B2 (ja) | ||
| CA2315259A1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| US6521254B2 (en) | Single-dose antihistamine/decongestant formulations for treating rhinitis | |
| EP0154639B1 (en) | Pharmaceutical compositions having appetite reducing activity and a process for their preparation | |
| US4564614A (en) | Antiinflammatory methods | |
| US4559326A (en) | Antiinflammatory compositions and methods | |
| US3143463A (en) | 1-(para-halophenyl)-2-loweralkyl-amino propane: weight reducing composition and method | |
| GB2197198A (en) | Analgesic preparations | |
| DK166947B1 (da) | Forbedrede piroxicamholdige praeparater med antiinflammatorisk virkning | |
| Lien et al. | Preventing potential drug interactions in community pharmacy | |
| KR20010021796A (ko) | ì íì± ìžë¡í ë ì¬í¡ì ìµì ì (ïœïœïœïœ)륌 ì¬ì©íëì¬ì¥ ì§íì ì¹ë£ ë° ìë°©ë² | |
| TW200539859A (en) | Methods for increasing neurotransmitter levels using hydroxycitric acid | |
| Sacchetti et al. | Effect of analgesic agents on emptying of the gallbladder in man | |
| JPS6081127A (ja) | é£æ¬²æå¶å€ | |
| US4229477A (en) | Pharmaceutical compositions containing bromhexine and method of treating diabetic nephropathy therewith | |
| EP0445920A2 (en) | Use of ethoxy phenoxy acetic acid derivatives against diabetes | |
| JP2586542B2 (ja) | çã®ç¬¬åèå€äœã®æ²»çå€ | |
| Rabbani | Pharmacology in 7 days for medical students | |
| RU2234917C2 (ru) | ТеÑапевÑОÑеÑкОе ÑÑеЎÑÑва | |
| JP2002542198A (ja) | æèºè¬ããã³æ°åå€åã®å®å®è¬ãšããŠã®ã«ããžãŠã ããã³ç¹ã«å¡©åã«ããžãŠã ã®äœ¿çš |